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Sensitization profiles of rhinitis, non-rhinitis healthy subjects and asthmatic 
subjects (from Singapore and Malaysia respectively) against three major mite allergens 
Der p 1, Der p 2 and Blo t 5 were studied using enzyme-linked immunosorbent assay 
(ELISA). The sensitization profile of rhinitis subjects to the domestic mite allergens 
used in this study was as follow: Blo t extract +: 91 / 124 (73%); Blo t 5 +: 62 / 124 
(50%); Der p extract +: 61 / 124 (49%); Der p 1 +: 53 / 124 (43%); Der p 2 +: 45 / 124 
(36%).  The non-rhinitis healthy subjects’ sensitization profile was as follows: Blo t 
extract +: 60 / 105 (57%); Blo t 5 +: 24 / 105   (23%); Der p extract +: 38 / 105 (36%); 
Der p 1 +: 14 / 105 (13%); Der p 2 +: 17 / 105 (16%). Study on Malaysian subjects 
showed that 39% of the adult patients with asthma were sensitized to Der p 1; 32% to 
Der p 2; 37% to Blo t 5. The corresponding sensitization profiles in the asthmatic 
children were 57% to Der p 1, 39% to Der p 2 and 90% to Blo t 5. Therefore, these 
allergens are important sensitizing agents and should be included in component-
resolved diagnosis of mite sensitization. 
 Besides that, a unique allergen from Blomia tropicalis (Blo t), Blo t 19 was 
identified through cDNA library screening. Blo t 19 is a small (around 7 kD) and 
cysteine-rich protein. Recombinant form of Blo t 19 was a minor allergen.  Sequence 
analysis revealed that Blo t 19 had high sequence (76%) similarity with Ascaris suum 
antibacterial factor (ASABF). Blo t 19 is a possible CSαβ-type peptide based on 
sequence comparison with ASABF. Blo t 19 is also the first protein not identified 




A Blo t 19-specifc monoclonal antibody which was useful for detection of Blo t 
19 in western blot and ELISA was successfully raised using a combination of DNA 
immunization and protein boost in mice. However, the purification procedures of 
native Blo t 19 using this monoclonal antibody remain elusive. 
It was observed that conventional method of immunizing the mice failed to 
induce antibody against Blo t 19. Besides that, the strain of mice could influence the 
chance of inducing antibody against Blo t 19. 
In short, this study revealed the sensitization profiles of rhinitis and asthmatics 
subjects in this region; identified a unique Blo t allergen, Blo t 19, and successfully 
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1.1 Background of the study 
 
The prevalence of allergic diseases such as asthma and allergic rhinitis increased 
significantly in the early 90s (Sears, 1997; ISAAC, 1998 (a-b)); Linneberg et al., 1999; 
Linneberg et al., 2000; Strannegård & Strannegård, 2001; Babu & Arshad, 2003). 
Although several studies from Italy, Switzerland and Australia recently indicated that 
at least the increasing trend has stopped in the respective studied populations, these 
allergic diseases remain an important health issue in the population (Ronchetti et al., 
2001; Braun-Fahrlander et al., 2003; Toelle et al., 2004). Allergic diseases such as 
asthma and allergic rhinitis not only cause a drop in the quality of life of the people 
affected by them but could also be fatal at times in the case of asthma (Baraniuk, 1997; 
Holgate, 1999). Various epidemiological studies around the world showed that the 
prevalence of allergic diseases ranged from around 2% to 30% in some countries 
(ISAAC, 1998 (a); Janson et al., 2001). The difference in the prevalence could be due 
to genetic predisposition and environmental factors such as life style (Barnes & Marsh, 
1998; von Mutius et al., 1998; Howard et al., 1999; Zhang et al., 1999; Cookson & 
Moffatt, 2000; Janson et al., 2001; Strannegård & Strannegård, 2001; Cookson, 2002; 
Yazdanbakhsh et al., 2002). 
Among the environmental factors, the presence or absence of allergens in the 
surroundings is a determining factor whether one will be sensitized and/or develop an 
allergic disease (Platts-Mills & Chapman, 1987; Lau et al., 1989; Sporik et al., 1990). 




mites (family Acaridae, Glycyphagidae and Chortoglyphidae)), especially 
Dermatophagoides pteronyssinus (Der p), Dermatophagoides farinae (Der f), and 
Blomia tropicalis (Blo t) are major sources of allergens that cause allergic asthma and 
rhinitis (Voorhorst et al., 1967; Platts-Mills & Chapman, 1987; Platts-Mills & de 
Weck, 1989). Due to the fact that domestic mites are very common in indoor 
environment around the world (Ho, 1986; Hurtado & Parini, 1987; Arlian et al., 1992; 
Zhang et al., 1997; Colloff, 1998 (a)), people are easily exposed to mite allergens and 
sensitized to them (Lau et al., 1989; de Groot et al., 1990; Sporik et al., 1990). 
Therefore, it is important to study the mite sensitization in order to better understand 
and control the rise of allergic diseases. 
The advent of advances in molecular biology allowed various allergens to be 
identified and cloned from domestic mites (Thomas & Smith, 1998; Thomas & Smith 
1999; Thomas et al., 2002; Kawamoto et al., 2002 (a)). Currently, around 19 different 
groups of allergens had been identified from domestic mites (Thomas et al., 2002; 
Kawamoto et al., 2002 (a); Mills et al., 1999; Lim et al., 2002; Yi et al., 2002; Lee et 
al., 2002; Kawamoto et al., 2002 (b), Flores et al., 2003; Mora et al., 2003; Cheong et 
al., 2003 (a-b); Saarne T et al., 2003; http://www.allergen.org/List.htm; Weber et al., 
2003). The identification of individual allergens are important for better diagnosis and 
treatment of mite allergy.    
Although there were a number of studies on the prevalence of mite 
sensitization (Woodcock & Cunnington, 1980; Ho et al., 1995; Leung et al., 1997; 
Baratawidjaja et al., 1999; Chew et al., 1999 (a)), mite crude extracts were used as the 
reagents. The usefulness of recombinant and purified domestic mites allergens as 




Monoclonal antibody is a valuable reagent in mite allergy study (Chapman et 
al., 1987; Luczynska et al., 1989; Härfast et al., 1992; Yunginger  & Adolphson, 1992; 
Ovsyannikova et al., 1994; Ferrándiz et al., 1995; Shen et al., 1995; Shen et al., 1996; 
Ferrándiz et al., 1997; Peng et al., 1998; Tsai et al., 2000; Labrada et al., 2002; Park et 
al., 2002; Parvaneh et al., 2002; Trombone et al., 2002; Ramos et al., 2003). Various 
methods had been employed to generate monoclonal antibody (Köhler & Milstein, 
1975; Smith, 1985; McCafferty et al., 1990; Clackson et al., 1991; Marks et al., 1991). 
These include the conventional fusion of spleenocytes from immunized mice and 
myeloma cells to generate monoclonal antibody producing hybridomas and 
unconventional phage display method (Köhler & Milstein, 1975; Smith, 1985; 
McCafferty et al., 1990; Clackson et al., 1991; Marks et al., 1991). 
1.2 Overall objectives of the study 
The overall objectives of the study were as follows: 
• To study the sensitization profiles of rhinitis and non-rhinitis healthy subjects 
in Singapore. 
• To study the sensitization profiles of adult asthmatics and children asthmatics 
in Malaysia. 
• To isolate a unique allergen from Blo t using cDNA library screening. 
• To raise monoclonal antibodies specific against the unique allergen, Blo t 19, 
identified in cDNA library screening. 
 
1.3 Overall significance of the study 
 
Firstly, this study is one of the first studies reporting the sensitization profiles 




Der p 1, Der p 2 and Blo t 5. This study showed that Blo t 5 sensitization was generally 
more prevalent among these subjects compared to Der p 1 and Der p 2. This further 
established the importance of Blo t allergens in relation to allergic diseases in this part 
of the world. More importantly, it also showed that these three allergens are important 
reagents in component-resolved diagnosis of mite sensitization. 
 Secondly, the identification of Blo t 19 from Blo t mite contributed to the effort 
of identification of a more complete and representative spectrum of allergens from 
domestic mites. Blo t 19 is also the first protein not identified among nematodes to be 
having a very high amino acid sequence similarity with an antibacterial factor from 
Ascaris suum, Ascaris suum antibacterial factor (ASABF). ASABF could be 
considered distantly related to insect defensins (Dimarcq et al., 1998). ASABF has 
antibacterial activity against a range of bacteria and yeast (Zhang et al., 2000). 
 Thirdly, this study also successfully raised a Blo t 19-specific monoclonal 
antibody. Nonetheless, it also showed that generation of monoclonal antibody against 
Blo t 19 was difficult despite different methods employed: DNA immunization, protein 
immunization through different routes. Further optimization of the immunization 
schedule and methods of immunization could probably increase the chance of 








2 Literature review 
2.1 Allergy & allergic airway diseases 
Allergy is a complex phenomenon of the human immune response. The term 
“allergy” was first introduced by von Pirquet in 1906 to describe biological responses 
which could lead to either immunity or allergic disease (Kay, 2001). Today, the term 
“allergy” is used almost interchangeably with IgE-mediated allergic responses (Kay, 
2001). Nevertheless, effort has been made to standardize the definition of this term 
(Johansson et al., 2001). The more acceptable definition for allergy is: allergy is a 
series of hypersensitive reactions caused by the Th2-skewed immune system of the 
body (Figure 1) (Holgate, 1999; Holt et al., 1999; Johansson et al., 2001). In certain 
cases, these reactions could be also cell-mediated, such as in the case of contact 
dermatitis where sensitized lymphocytes played a major role (Johansson et al., 2001). 
In IgE-mediated allergy, elevated levels of IgE in the patient’s sera induce 
allergic responses. These include wheezing, rhinoconjunctivitis, gastrointestinal 
symptoms, lesions in the skin (eczema) and anaphylaxis. IgE-mediated allergic 
diseases include allergic asthma, allergic rhinitis, allergic conjunctivitis, atopic eczema 
/ dermatitis syndrome (AEDS) and urticaria (Johansson et al., 2001). 
Substances (mainly proteins, and some carbohydrate) that induce immunological 
response once encountered by the body are known as antigens. Allergens are antigens 
that induce allergic responses (Johansson et al., 2001). The important allergens found 




(Voorhorst et al., 1967; Kay, 2001; Thomas et al., 2002). Allergens generally come 
into contact with humans through the mucosal surfaces (Holgate, 1999). 
The prevalence of allergy and allergic diseases around the world is generally on 
the rise in the recent years due to change in environment factors and life style 
(Robertson et al., 1991; Åberg et al., 1995; Sears, 1997; Boner et al., 1998; Lundbäck, 
1998; ISAAC, 1998 (a-b); von Mutius et al., 1998; Linnerberg et al, 1999; Linneberg 
et al., 2000; Kay, 2001). Change of life style towards more “westernized” one and 
improved in cleanliness have been linked with the increase in the prevalence of allergy 
and allergic diseases (von Mutius et al., 1998; Strannegård & Strannegård, 2001; 
Yazdanbakhsh et al., 2002) 
The diagnosis of allergy is performed by measuring the free or cell-bound IgE 
using in vivo and in vitro diagnosis methods. In vivo diagnoses of allergy is skin prick 
tests (SPT) whereas  in vitro methods, include radioallergosorbent assay (RAST), 
enzyme-linked immunosorbent assay (ELISA) and Pharmacia CAP system (Wide et 
al., 1967; Johansson et al., 1999; Bousquet et al., 2001). 
2.1.1 Immunoglobulin E (IgE) 
Immunoglublin E (IgE) (originally known as γE-Globulin (Ishizaka et al., 1966 
(a)) or IgND (Johansson, 1967) when first discovered) was discovered between 1966 
and 1967 (Ishizaka et al., 1966 (a), Ishizaka et al., 1966 (b), Johansson, 1967). It was 
first reported to be associated with asthma by Johansson (Johansson, 1967) and at the 
same time an assay (radioallergosorbent test (RAST)) was developed to detect this 
immunoglobulin in the sera (Wide et al., 1967). Later in 1968, this new class of 
immunoglobulin was officially named IgE (Bennich et al., 1968). 
Normal, non-atopic individuals have very low IgE titre. Normal individuals 




100-150 KU / l of IgE, then he/she is considered above normal (Bousquet et al., 2001). 
The typically median level of total IgE is 200-400 kU / l in normal atopic diseases and 
a level of more than 1000 kU / l suggests various complications (Aalberse, 2000). The 
half-life of IgE in sera is less than two days while IgE bound to mast cells in the skin 
can last for around 10 days (Platts-Mills T, 2001).  
The synthesis of IgE is shown in Figure 1. Allergen-specific IgE is synthesize 
as a result of the interactions of B cell – Th2 cell – mast cells / basophils, upon the 
presentation of allergen to Th2 cell by antigen presenting cell (APC) (Yssel et al., 
1998; Corry & Kheradmand, 1999; Holgate, 1999; Holt et al., 1999). 
Various studies have shown the association of IgE level (total IgE or allergen-
specific IgE) to allergic diseases (Burrows et al., 1989; Sears et al., 1991; Kotaniemi-
Syrjänen et al., 2003). For instance, Sears and colleagues showed that in asthmatic 
children, IgE levels are associated with physician-diagnosed asthma and bronchial 
hyperresponsiveness (BHR) (Sears et al., 1991). Nonetheless, the correlation of total 





Figure 1: Regulations of IgE synthesis and allergic responses (adapted from Yssel 
et al., 1998; Corry & Kheradmand, 1999; Holgate, 1999; Holt et al., 1999). 
 
2.1.2 Allergic rhinitis 
Allergic rhinitis is a term used to describe hypersensitivity of the nose caused 
by immunological reactions of the body which usually resulting in the production of 
antigen-specific IgE (Johansson et al., 2001). Allergic responses involved in allergic 
rhinitis include itch, sneeze, congestion, drip, fatigue and dysfunction (Baraniuk, 1997). 
The allergens that cause allergic rhinitis are inhaled allergens which include pollen, 
acarids, animal dandruff and fungi (Baraniuk, 1997; Passàli et al., 2001).  
House dust mites and storage mites played a major role in allergic rhinitis. 
Domestic mites that are most commonly found in homes in various parts of the world 
are Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia 




1992; Malainual et al., 1995; Puerta et al., 1996 (a); Arlian et al., 1999; Chew et al., 
1999 (b); Arlian, 2000; Sopelete et al., 2000; Passàli et al., 2001). Majority of allergic 
rhinitis patients are sensitized to mites (Bousquet et al., 2001). 
Various studies have shown that allergic rhinitis and asthma often coexist 
(Lombardi et al., 2001; Linneberg et al., 2002). Some studies managed to show that 
allergic rhinitis is a risk factor for asthma (Leynaert et al., 1999; Guerra et al., 2002; 
Linneberg et al., 2002, Torén et al., 2002). 
2.1.3 Allergic asthma 
A worldwide study on the prevalence of asthma has yield wide range of 
differences (ISAAC, 1998 (a)). The ISAAC study, performed in 56 countries, showed 
that the prevalence of asthmatic symptoms among children aged 13-14 years ranged 
from less than 5% in Indonesia to over 30% in the United Kingdom (ISAAC, 1998 (a)). 
An additional report by the same study, focusing specifically on the prevalence of 
asthma worldwide (ISAAC, 1998 (b)) had showed similar findings: the prevalence of 
asthma was up to 15-folds differences between countries (ISAAC, 1998 (b)). In this 
report by ISAAC, study subjects aged 6-7 years were also included besides the 13-14 
years group. The prevalence rate ranged from 1.6-3.0% in Albania, Estonia, Ethiopia, 
Indonesia, Iran, Poland, Russia, South Korea and Uzbekistan to 20.7-28.2% in 
Australia, New Zealand, Oman, Peru, Singapore and the United Kingdom (ISAAC, 
1998 (b)). Although the prevalence of asthma varies from country to country, its 
burden is important and should not be overlooked. 
Besides having a high prevalence, asthma is a common illness that could 
seriously affect the quality of life of the sufferers. Both wheezing at night and night 




An individual with allergic asthma has the tendency to develop airway 
hyperresponsiveness (AHR) in the lung, airway inflammation and allergic sensitization 
(elevation in the antigen-specific IgE titres) (Corry, 2002). When IgE is involved in the 
pathogenesis of asthma, the disease is known as allergic asthma. Allergic asthma can 
be differentiated from non-allergic asthma based on skin prick tests results (Romanet-
Manent et al., 2002). It is also known that allergic asthma is strongly linked to genetic 
factors (Zhang et al., 1999; Cookson & Moffatt, 2000). 
A study performed by Romanet-Manent et al. clearly showed the clinical 
differences between allergic asthma and non-allergic asthma (Romanet-Manent et al., 
2002). According to the study, allergic patients were significantly younger than non-
allergic patients and there was a female-biased in non-allergic asthma (more female 
compared to male). Besides that, allergic asthma was more influenced by the change of 
seasons compared to non-allergic asthma. Although in the study, no significant 
difference was observed on the prevalence of rhinitis among the allergic and non-
allergic asthmatics, the authors observed that there was a trend of higher rate of 
sneezing in allergic asthmatics (Romanet-Manent et al., 2002). The other important 
observation by the same study was that non-allergic asthmatics tend to have more 
serious asthma symptoms compared to allergic asthmatics. 
On the physiological level, Walker et al. showed that allergic asthmatics had 
elevated levels of interleukin-4 (IL-4) and interleukin-5 (IL-5) whereas the non-
allergics had higher levels of interleukin-2 (IL-2) and IL-5. The elevation in IL-4 in 
allergic asthmatics resulted in the elevation of IgE in the sera of these patients (Walker 
et al., 1992).  
Besides inducing the synthesis of IgE (Figure 1), IL-4 is also involved in 




goblet-cell metaplasia by acting directly on the airway smooth muscle and epithelium 
(Corry, 2002). Nevertheless, the role of IL-4 in this pathway is not as important 
compared to another interleukin – interleukin-13 (IL-13) (Wills-Karp et al., 1998; 
Grünig et al., 1998). In fact, it has been shown recently that IL-13 causes airway 
hyperreactivity and mucus over-production in asthma (Kuperman et al., 2002) 
There has been an increasing number of reports, showing that allergic asthma 
and allergic rhinitis are a uniform airway disease (Bousquet et al., 2001; Guerra et al., 
2002; Lundblad, 2002; Linneberg et al., 2002). 
2.2 Sensitization: a general definition 
Antigen specific IgE secreted by plasma cells binds with the Fcε receptor 
(FcεRI) on the surface of mast cells and blood basophils (Baraniuk, 1997). These 
“sensitized” cells upon second encounter with the same allergen undergo degranulation, 
releasing active mediators such as histamine that exert biological effects on 
surrounding tissues (Kuby, 1992). Sensitization can also be defined as a primary 
response to allergens which primarily induce the differentiation of CD4+ T cells to T 
helper 2 (TH2) cells (Figure 1) (Valenta 2002; Constant et al., 2000). The first 
definition takes into account the downstream process of sensitization only whereas the 
latter definition gives a more thorough picture from the upstream to downstream of the 
whole process of sensitization. The main indication that one is sensitized is the 
presence of allergen-specific IgE in the sera and / or on mast cells and basophils. 
Therefore, a subject is classified as sensitized if he / she is positive in skin prick tests 





2.2.1 Prevalence of mite sensitization 
The prevalence of mite sensitization in the general population varies from 
country to country and is under the influence of different climatological conditions 
(Murray et al., 1985; Burney et al., 1997). A study conducted on randomly selected 
individuals across 37 centres in 16 countries by The European Community Respiratory 
Health Survey revealed that the prevalence of Der p sensitization ranged from 6.7% to 
35.1% (Burney et al., 1997). Nevertheless, the prevalence of mite sensitization was 
still among the highest compared to other allergens in the same study (Cat: 2.7%-
14.8%; Grass: 8.1%-34.6%; Cladosporium spp: 0.3%-13.6%) (Burney et al., 1997). 
Mite sensitization is more prevalent among subjects from humid areas compared to 
subjects from “dry areas” (Murray et al., 1985). This was largely due to the fact that 
domestic mites generally survive better in humid conditions (Arlian et al., 1998 (a-b); 
Bousquet et al., 2001). Therefore, exposure to mites is more possible and frequent in 
humid areas. 
The prevalence of mite sensitization among patients with allergic diseases 
offered a different picture. Various studies on the mite sensitization among these 
patients showed that the prevalence was very high (70-90%) and correlated well with 
the disease state (Rizzo et al., 1993; Stanaland et al., 1994; Ho et al., 1995; Droste et 
al., 1996; Ferrándiz et al., 1996; Nelson et al., 1996; Boulet et al., 1997; Leung et al., 
1997; Tsai et al., 1998 (a); Baratawidjaja et al., 1999; Mori et al., 2001; Verini et al., 
2001). Mite sensitization has been recognized as a risk factor for the development of 
allergic diseases, such as allergic asthma and allergic rhinitis (Sporik et al., 1990; Peat 
et al., 1996; Leung et al., 1997; Boner et al., 1998; Lynch et al., 1998; Scalabrin et al., 
1999; Chou et al., 2002; del Giudice et al., 2002; Wong et al., 2002). Association 




association between sensitization to mite and bronchial responsiveness (Janson et al., 
2001). The association of allergenic sensitization with the development of allergic 
diseases, especially asthma and rhinitis is well accepted now (Burrows et al., 1989; 
Yssel et al., 1998; Oettgen & Geha, 2001). This is to be noted that not all sensitization 
leads to disease (Wahn, 2000). Other factors such as genetic factor, environment and 
lifestyle, are also involved (Sporik et al., 1999; von Mutius et al., 1998; Kurz et al., 
2000; Wahn, 2000; Kay, 2001; Strannegård & Strannegård, 2001; Kauffmann et al., 
2002; Yazdanbakhsh et al., 2002).  
2.2.2 Crude extracts versus recombinant / purified allergens 
There are basically two choices of allergens in sensitization study, the first one 
being the crude extracts and the second being recombinant or purified allergens. 
Studies of mite sensitization in the population have traditionally been carried out using 
crude extracts prepared from the allergen sources (either prepared in house or obtained 
commercially) (Pepys et al., 1967; Woodcock & Cunnington., 1980; Murray et al., 
1985; Puerta et al., 1991; Rizzo et al., 1993; Stanaland et al., 1994; Ho et al., 1995; 
Droste et al., 1996; Ferrándiz et al., 1996; Nelson et al., 1996; Boulet et al., 1997; 
Burney et al., 1997; Leung et al., 1997; Tsai et al., 1998 (a); Baratawidjaja et al., 1999; 
Chew et al., 1999 (a); Kuo et al., 1999; Yi et al., 1999; Mori et al., 2001; Verini et al., 
2001; Court et al., 2002; Jaén et al., 2002; Müsken et al., 2002). Dermatophagoides 
pteronyssinus (Der p) mite crude extracts has traditionally been used as a 
representation of mite allergens in mite sensitization studies (Pepys et al., 1967; 
Woodcock & Cunnington., 1980; Murray et al., 1985; Puerta et al., 1991; Droste et al., 
1996; Ferrándiz et al., 1996; Nelson et al., 1996; Boulet et al., 1997; Burney et al., 
1997; Leung et al., 1997; Baratawidjaja et al., 1999; Chew et al., 1999 (a); Kuo et al., 




This was largely due to the reason that Der p mite dominates the indoor mite 
populations in various parts of the world and was long known to be a major source of 
allergens (Voorhorst et al., 1967; Maunsell et al., 1967; Arlian et al., 1992; Malainual 
et al., 1995; Colloff, 1998 (a); Arlian et al., 1999; Chew et al., 1999 (b)). Nonetheless, 
lately, the importance of other domestic mites was recognized and crude mite extracts 
from other mites such as Dermatophagoides farinae (Der f) and Blomia tropicalis (Blo 
t) have been included along with Der p (Rizzo et al., 1993; Stanaland et al., 1994; Ho 
et al., 1995; Ferrándiz et al., 1996; Nelson et al., 1996; Tsai et al., 1998 (a); 
Baratawidjaja et al., 1999; Mori et al., 2001). 
The use of recombinant or purified allergens as reagents to study sensitization 
profile is relatively new compared to the use of crude extracts. Recombinant allergens 
were only available with the advancement in recombinant DNA technology. 
Nonetheless, various investigators have started to realize the advantages of such 
allergens confer in their studies (Valenta & Kraft, 1995; Kraft et al., 1999; Heiss et al., 
1999; Johansson et al., 1999; Tsai et al., 1998 (a); Valenta & Vrtala, 1999; Valenta et 
al., 1999 (a); Kronqvist et al., 2000; Kazemi-Shirazi et al., 2002; Valenta, 2002 (a-b); 
Simpson et al., 2003). Recombinant allergens not only gave more consistent results in 
sensitization studies but also are valuable reagents for immunotherapy and vaccination 
(Kraft et al., 1999; Valenta et al., 1999 (b); Kazemi-Shirazi et al., 2002).  
As a matter of fact, a combination of recombinant or purified allergens could 
potentially replace the use of crude extract in sensitization study, as demonstrated by 
Laffer et al. using recombinant pollen and birch allergens (recombinant pollen 
allergens: Phl p 1, Phl p 2, Phl p 5; recombinant birch allergen: Bet v 2) where they 
showed that the combination of these allergens accounted for 94.5% (173 / 183) of 




study conducted by Valenta et al. where 97 / 98 grass pollen-allergic patients were 
identified using 2 recombinant pollen allergens (Phl p I; Phl p V) and 1 grass 
recombinant allergen (profilin) (Valenta et al., 1992). However, another study by 
Niederberger et al. only managed to detect 59% of grass pollen-allergic subjects 
(Niederberger et al., 1998). This could be due to cohort differences and experimental 
design. Besides that, the choice on the panel of recombinant allergens could also 
influence the sensitivity of the detection. If some major allergens are being left out of 
the panel, obviously the sensitivity of the test will be reduced as well. Logically, a 
combination of purified native allergens also showed good results: over 90% of extract 
positive subjects were detected (van Ree et al., 1998; van Ree et al., 1999). To date, no 
similar studies were conducted on recombinant or purified mite allergens. 
2.3 Domestic mites 
Domestic mites consist of various free-living mites that are found living in 
houses. This includes house dust mites (HDM) (family Pyroglyphidae) and storage 
mites (family Acaridae, Glycyphagidae and Chortoglyphidae) (Colloff et al., 1992; 
Platts-Mills et al., 1992). Pyroglyphidae mites are also known as nidicolous mites as 
most of them lived in the nests of birds and mammals (Warner et al., 1999). Acaridae 
and Glycyphagidae mites are known as storage mites mainly because they are often 
found in large numbers in barns, silos, and other habitats where agricultural products 
are stored (Warner et al., 1999). They are well characterized morphologically 
(Voorhorst et al., 1967; Colloff et al., 1992; Colloff, 1998 (b)). Human and animal 
skin scales are the major food for Pyroglyphidae mites while decaying plants and 
similar products are food for Acaridae and Glycyphagidae mites (Warner et al., 1999). 
Nonetheless, a study by Naspitz et al. showed that both HDM (Dermatophagoides 




detected in dust samples collected from children scalps, indicating not only 
Pyroglyphidae mites but also Glycyphagidae mites could feed on human dandruff 
(Naspitz et al., 1997). Domestic mites that were reported to be prevalent in various 
home environments around the world were mainly from family Pyroglyphidae and 
Glycyphagidae (Hurtado et al., 1987; Platts-Mills & Chapman, 1987; Arlian et al., 
1992; Puerta et al., 1996 (a); Mariana et al., 1996; Arlian et al., 1999; Chew et al., 
1999 (b); Arlian, 2000; Sopelete et al., 2000).   
In general, domestic mites grow best under hot (above 23°C) and humid (80% 
relative humidity) conditions (Platts-Mills & Chapman, 1987; Arlian et al., 1998 (a-b); 
Bousquet et al., 2001).  Example of exception to the rule is Euroglyphus maynei which 
had been shown to be unable to survive at relative humidity higher than 65% (Arlian et 
al., 1998 (a)). Domestic mites require high humidity to survive (Hart, 1998) because 
their main source of water supply comes from water vapour. Only at humidity of 65-
70%, sufficient water could be extracted from the air in their surroundings (Arlian, 
1992). 
Although the term “domestic mites” was proposed to be used to describe house 
dust mites and storage mites collectively (Platts-Mills et al., 1992) and has since been 
used by various investigators (Naspitz et al., 1997; Müsken et al., 2002), throughout 
the literature, the term “dust mite” was commonly used to describe storage mites as 
well (Eriksson et al., 1998; Eriksson et al., 1999; Gafvelin et al., 2001). This text will 
adopt the term “domestic mites” to describe house dust mites and other non-
pyroglyphidae mites collectively and reserve the term HDM for Pyroglyphidae mites 
only for future discussion. 
There exist two schools of thought on the taxonomy of domestic mites in the 




Olsson & van Hage-Hamsten, 2000). The former system was mainly followed by 
Colloff et al., and Olsson et al. (Colloff 1998 (b); Colloff & Spieksma, 1992; Olsson & 
van Hage-Hamsten, 2000) while the latter was used by Arlian and colleagues (Arlian 
& Platts-Mills, 2001). Nonetheless, the differences between the two systems were not 
significant. The differences between both systems were outlined in Table 1 (Table 1), 
using Blomia tropicalis as an example. Since more information was available on the 
system used by Colloff (Colloff, 1998 (b); Olsson & van Hage-Hamsten, 2000), further 
discussion on the taxonomy of domestic mites will be based on this system.  
 
 Arlian et al., 2001 Colloff, 1998 (b) 
Kingdom Animalia Animalia 
Phylum Arthropoda Arthropoda 
Subphylum Chelicerata Chelicerata 
Class Arachnida Arachnida 
Subclass - Acari 
Order Acari Acariformes 
Infraorder - Sarcoptiformes 
Suborder Astigmata Astigmata 
Superfamily - Glycyphagoidea 
Family Echymyopodidae Glycyphagidae 
Genus Blomia Blomia 
Species tropicalis tropicalis 
Table 1: Differences between two classification systems, using Blomia tropicalis as 
an example (based on Arlian et al., 2001; Colloff, 1998 (b); Olsson & van Hage-
Hamsten, 2000). 
 
As shown in Table 1, domestic mites belong to Class Arachnida, indicating that 
the mites are more closely related to spiders than to insects. Mites under the suborder 
Astigmata lack specialized respiratory organs (Colloff & Spieksma, 1992).  
Though house dust had been shown to cause skin reactions in asthmatic 
patients as early as in 1921 and 1922 respectively (Kern, 1921; Cooke, 1922), it was 
not until around 1967 when Der p was identified to be the major allergen contributor in 




studies had been performed to study mites in the house dust and their relevance to 
allergy. It is now known that domestic mites that play major roles in allergy are mainly 
from family Pyroglyphidae: Dermatophagoides pteronyssinus (Der p), 
Dermatophagoides farinae (Der f), and from family Glycyphagidae: Blomia tropicalis 
(Blo t). To date, around 19 different groups of allergens had been identified in 

















Figure 2: Taxonomy of Blomia tropicalis and Dermatophagoides pteronyssinus 
2.3.1 Dermatophagoides pteronyssinus (Der p) 
Mites of the genus Dermatophagoides was first described by Bogdanov in 1864 
(Colloff, 1998 (b)). Morphologically, as with other mites under the family 
Pyroglyphidae (Figure 2), Der p has “fingerprint” pattern of striations on its body. 
According to Colloff (Colloff 1998 (b)), mites in the genus Dermatophagoides are 
characterized by the difference in length of setae present on their body, and the 




and dandruff of animals and human beings. They live permanently in house dust and 
thus the term house dust mite (HDM) has often been used to describe collectively all 
the mites that are found consistently in house dust. Nevertheless, only six out of the 
thirteen species of mites from family Pyroglyphidae are distributed worldwide (Platts-
Mills & de Weck, 1989; Colloff, 1998 (b)). These include Dermatophagoides 
pteronyssinus, Dermatophagoides farinae, Hirstia domicola, Malayoglyphus 
intermedius, Sturnophagoides brasiliensis. and Euroglyphus maynei (Ho, 1986; Platts-
Mills & de Weck, 1989; Colloff 1998 (b)). 
Der p was the earliest known mite to have a role in causing allergy (Voorhorst 
et al., 1967; Maunsell et al., 1967). It was later known that mite faeces are a major 
source of house dust allergens and the allergen in the faecal pellet was mainly Der p 1, 
one of the major allergen from Der p (Tovey et al., 1981).  
2.3.2 Blomia tropicalis (Blo t) 
Storage mite, Blo t, belongs to the Family Glycyphagidae (Figure 2). 
Morphologically, like other mites from family Glycyphagidae, Blo t has a smooth 
cuticle, body covered with minute papillae, and long serrated dorsal setae (Colloff & 
Spieksma, 1992; Colloff, 1998 (b)). It is prevalent in the tropical region (Chew et al., 
1999 (b); Puerta et al., 1996 (b)). Blo t, like other mites species, survives best under 
high humidity and temperature (Bousquet et al., 2001). 
 The significance of this mite in allergy has been extensively studied in the 
recent years by various investigators (Arlian et al., 1993; Stanaland et al., 1994; 
Arruda et al., 1995; Puerta et al., 1996 (b); Caraballo et al., 1997; Chew et al., 1999 (a); 
Shek et al., 1999; Yi et al., 1999; Yi et al., 2002; Angus et al., 2002; Ramos et al., 
2001; Medeiros et al., 2002; Ramos et al., 2003). As a matter of fact, various 




and subtropical regions (Caraballo et al., 1993; Arruda et al., 1995; Puerta et al., 1996; 
Leung & Lai, 1997; Platts-Mills et al., 1997; Zhang et al., 1997; Fernández-Caldas, 
1997; Arruda et al., 1997; Caraballo et al., 1997; Kuo et al., 1999; Yi et al., 1999; 
Chew et al., 1999 (b); Yi et al., 1999; Arlian & Platts-Mills, 2001; Ramos et al., 2001; 
Medeiros et al., 2002). 
 
2.4 Allergens from domestic mites 
2.4.1 Overview of mite allergens 
The importance of dust sensitization in bronchial asthma was first noticed by 
Dr. Richard Kern in 1921 (Kern, 1921). It was not until around 1964-1967 when 
Voorhorst and co-workers showed that dust sensitization was actually mainly 
sensitization to allergens from HDM, Der p (Voorhorst et al., 1967). Maunsell et al. 
and Pepys et al. also obtained similar findings (Maunsell et al., 1967; Pepys et al., 
1967). In addition, Maunsell et al. and Pepys et al. also showed the presence of 
sensitization to storage mites and other mites (Glycyphagus domesticus, Acarus siro in 
both studies and Tyrophagus putrescentiae in Maunsell et al.’s study) among subjects 
tested (Maunsell et al., 1967). Nonetheless, the sensitization frequencies to these mites 
in their findings were relatively small compared to sensitization to Dermatophagoides 
mites. These were some of the earliest available data on sensitization to storage mites. 
Besides, one interesting point to note was in Pepys et al.’s study, they used 
Dermatophagoides culinæ (now known as Dermatophagoides farinae) instead of 
Dermatophagoides pteronyssinus because they obtained similar results in skin prick 
tests using both extracts on 14 patients (Pepys et al., 1967). 
Over the years, various allergens from domestic mites were identified and 




on their sequence similarity, biochemical composition and molecular weight (King et 
al., 1994; Liebers et al., 1996; Arlian et al., 2001). As a general rule in naming 
allergens, the name of the allergen must use the following format: the first three letters 
of the genus are followed by the first letter of the species and the allergen number 
(King et al., 1994). For instance, group 1 allergens are called Der p 1 (group 1 allergen 
from Dermatophagoides  pteronyssinus), Der f 1 (group 1 allergen from 
Dermatophagoides farinae) and Blo t 1 (group 1 allergen from Blomia tropicalis) 
(Chapman & Platts-Mills, 1980; Heymann et al., 1986; Mora et al., 2003). The various 
groups of allergens have been, over the years, extensively reviewed by Thomas et al. 
and Kawamoto et al. (Thomas & Smith, 1998; Thomas & Smith 1999; Thomas et al., 










Der p, Der f, Der 
m, Der s, Eur m, 
Blo t, Pso o 
25000 Cysteine protease 60-100 
2 
Der p, Der f, Der s, 
Eur m, Lep d, Tyr 
p, Gly d, Pso o 
14000 Unknown (HE1 homologue) 80-100# 
3 Der p, Der f, Der s, Eur m, Blo t 25000-30000 Trypsin 
50-100 
 
4 Der p, Blo t, Eur m 57000 α-Amylase 30-46 
5 Der p, Blo t, Lep d 15000 Unknown 50-70 
6 Der p, Der f, Blo t 25000 Chymotrypsin 40 
7 Der p, Der f, Lep d 25000 Unknown 50 
8 Der p 26000 Glutathione-S-transferase (GST) 40 
9 Der p 30000 Collagenolytic serine protease 90 
10 Der p, Der f, Blo t, Lep d 
32930 (Lep d) 
37000 Tropomyosin 13-95 
11 Der f, Blo t 96000 Paramyosin 80 
12 Blo t 14000 Unknown, Chitin-binding protein? 50 
13 Blo t, Lep d, Aca s 15000 Fatty acid-binding protein 11-23 
14 Der f, Der p, Eur m 177000 (variable) 
Vitellogenin/apolipophorin-like, 
Mag3 39-70 
15 Der f 62500 98000 Chitinase 70 
16 Der f 55131 Gelsolin 18-47 
17 Der f ~53000 Ca-binding EF protein 35 
18 Der f 60000 Chitinase 54 
19 Blo t 7000 Anti-microbial peptide 10 
* Der f, Lep d 50007 (Lep d) Heat-shock protein 70 (Der f) α-tubulin (Lep d) 
12 (α-
tubulin) 
  # = IgE binding for Pso o 2 undetermined; * = undesignated 
Table 2: List of groups of allergens identified thus far in domestic mites  
+Note: Aca s: Acarus siro; Blo t: Blomia tropicalis; Der p: Dermatophagoides 
pteronyssinus; Der f: Dermatophagoides farinae; Der m: Dermatophagoides 
microceras; Der s: Dermatophagoides siboney; Eur m: Euroglyphus maynei; Gly d: 
Glycyphagus domesticus Lep d: Lepidoglyphus destructor; Pso o: Psoroptes ovis; 





2.4.1.1 Group 1 allergen 
 
Group 1 allergen (Table 2) was first identified by Chapman et al. in Der p 
(Chapman & Platts-Mills, 1980), later in Dermatophagoides microceras (Der m) (Lind, 
1986); in Dermatophagoides farinae (Der f) by Heymann et al. and Dilworth et al. 
(Heymann et al., 1986; Dilworth et al., 1991); in Euroglyphus maynei (Eur m) by Kent 
et al. (Kent et al., 1992); in Dermatophagoides siboney (Der s) (Ferrándiz et al., 1995) 
and recently in Blo t (Mora et al., 2003; Cheong et al., 2003 (a)). Besides that, group 1 
allergen has also been identified in sheep scab mite, Psoroptes ovis (Lee et al., 2002). 
Allergens from group 1 family have 221 to 223 amino acid residues and have a 
calculated molecular weight of 25000 daltons. (Chua et al., 1988; Dilworth et al., 1991; 
Chua et al., 1993; Mora et al., 2003). 
The characteristics of Der p 1 and Der f 1 have since been extensively studied 
(Lind, 1985; Lind, 1986; Chapman et al., 1987; van der Zee et al., 1988; Chua et al., 
1993; Hewitt et al., 1995; Hewitt et al., 1997; Gough et al., 1999). Sequence analysis 
revealed that group 1 allergens are cysteine proteases (Chua et al., 1988; Ando et al., 
1991; Heymann et al., 1986). Later study on Der p 1 revealed that it has a mixture of 
cysteine and serine protease activity (Hewitt et al., 1997). The enzymatic function of 
group 1 allergens could have a role to play in their allergenicity as studies have shown 
that group 1 allergens could cleave the human IgE receptor CD23 (Hewitt et al., 1995). 
The cleavage of CD23 might directly enhance the synthesis of IgE (Hewitt et al., 
1995). In addition, a study by Gough et al. also showed that mice immunized with 
proteolytically active Der p 1 had significant elevation in their total IgE compared to 
mice immunized with Der p 1 inhibited by cysteine protease inhibitor E-64 (Gough et 




destabilized the microenvironment of target tissues to one that was pro-allergic and 
thus induced the allergic responses (Gough et al., 1999). Although it was generally 
accepted that group 1 allergens are cysteine proteases, Blo t 1, which was recently 
cloned, as a cysteine protease, has yet to be proven to possess cysteine protease 
activity although having significant sequence identity with cysteine proteases from 
mites and other organisms (Mora et al., 2003). 
With the exception of Pso o I which had only been shown to bind IgE in 
infested sheep (Lee et al., 2002), other group 1 allergens have been shown to be 
allergenic in humans (Chapman & Platts-Mills, 1980; Heymann et al., 1986; Ferrándiz 
et al., 1995; Mora et al., 2002). In fact, group 1 allergen, especially Der p 1 and Der f 1 
are major allergens for humans (Chapman & Platts-Mills, 1980; Heymann et al., 1986). 
For Der p 1, Chapman and colleagues showed that three quarters of IgE antibody 
against Der p mite extract was directed against Der p 1 (Chapman & Platts-Mills, 
1980). Similar finding was also observed by Heymann and co-workers for Der f 1 
where 29 / 42 (69%) children and 55 / 63 (87%) adults who were allergic to Der f had 
IgE against Der f 1 (Heymann et al., 1986). Recently, Mora and co-workers also 
showed that recombinant Blo t 1 bound IgE from 13 / 21 (62%) Blo t mite extract 
positive patients (Mora et al., 2003). Although Der p 1 could account for most of the 
mite allergic subjects, there were clearly some who were not accounted for. This has 
driven other investigators to search for other allergens from the mites, which brings 
about the different groups of allergens identified so far. 
2.4.1.2 Group 2 allergens 
Group 2 allergen (Table 2) from Der p was first isolated by Lind using 
chromatography and was originally named as Dp X (Lind, 1985). The cDNA of Der p 




al., 1990). It was later named as Der p 2 under the guidelines by the WHO IUIS 
Allergen Nomenclature Subcommittee (King et al., 1994). Following the discovery of 
Der p 2, other group 2 allergens in other mites were also identified subsequently by 
various investigators: Der f 2 (Yasueda et al., 1986; Holck et al., 1986) in 
Dermatophagoides farinae; Lep d 2 (initially known as Lep d 1 when first described) 
(Ventas et al., 1992; van Hage-Hamsten et al., 1992; Varela et al., 1994; Schmidt et al., 
1995) in Lepidoglyphus destructor; Der s 2 in Dermatophagoides siboney (Ferrándiz et 
al., 1995); Tyr p 2 (Eriksson et al., 1998) in Tyrophagus putrescentiae; Eur m 2 
(shown to exist in Eur m extract by Morgan et al., 1997 but cloned by Smith et al., 
1999) in Euroglyphus maynei; Gly d 2 (Gafvelin et al., 2001) in Glycyphagus 
domesticus and Pso o 2 (Temeyer et al., 2002) in Psoroptes ovis. Group 2 allergen is a 
14 000 protein and shows various degrees of similarity with each other. For instance, 
Der p 2, Der f 2 and Eur m 2 were shown to share more than 80% amino acid sequence 
identity (Chua et al., 1996; Smith et al., 1999) whereas Lep d 2, Tyr p 2 shared lesser 
identity with Der p 2 (around 40% identity) (Gafvelin et al., 2001). Lep d 2 and Gly d 
2 shared up to 79% sequence identity indicating they are more phylogenetically linked 
to each other than to other mites (Gafvelin et al., 2001). The function of group 2 
allergens is largely unknown but there were indications that group 2 allergens might 
have similar function as epididymis-specific human HE1 gene product based on 
sequence analysis (Thomas & Chua, 1995). 
Group 2 allergens identified thus far, except for Pso o 2, are all considered 
major allergens (Lind, 1985; Yasueda et al., 1986; Heymann et al., 1989; Morgan et 
al., 1997; Lynch et al., 1997; Eriksson et al., 1998; Tsai et al., 2000; Kronqvist et al., 
2000; Gafvelin et al., 2001). For example, 87.8% (72 / 82) of asthmatic patients had 




(119 / 170) allergic patients in Venezuela had positive skin tests to recombinant Der p 
2 (Lynch et al., 1997). This also showed that group 2 allergens are the major 
sensitizing allergens among mite-allergic subjects. 
IgE binding activity for Pso o 2 was not determined. However, since Psoroptes 
ovis or the sheep scab mite, which is responsible for psoroptic scabies of cattle and 
sheep, rarely comes into contact with humans, the IgE binding activity of Pso o 2 is 
less relevant. Nonetheless, it shared around 40-54% amino acid sequence identity with 
other group II allergens (Temeyer et al., 2002).  
2.4.1.3 Group 3 allergens 
Der f 3 was purified and characterized by Heymann et al. (Heymann et al., 
1989). Der f 3 was suggested to be a trypsin-like protein based on sequence 
comparison with Der p 3, a functionally characterized trypsin in Der p (Smith et al., 
1996). It was reported that Der f 3 bound IgE in 16% (8 / 51) of the subjects tested 
(Heymann et al., 1989). 
The first indication of the existence of Der p 3 was reported by Stewart et al. 
where they showed Der p 3 shared sequence similarity with trypsin and chymotrypsin 
from other organisms (Stewart et al., 1989). Native Der p 3 was later isolated from Der 
p extract using gel filtration and the cDNA of Der p 3 was subsequently identified as 
well (Smith et al., 1994). Der p 3 has a predicted molecular weight of 24985 daltons 
(Smith et al., 1994). Der p 3 was later proven functionally as a trypsin (Stewart et al., 
1992). 
Besides, Der s 3 was also identified in Der s (Ferrándiz et al., 1997). The 
purified Der s 3 has a molecular weight of 30000 daltons with 73% of reactivity in 
patients’ sera tested (Ferrándiz et al., 1997). No further reports were available on Der s 




Blo t 3 was reported recently separately by two groups. (Flores et al., 2003; 
Cheong et al., 2003 (b)). The full length Blo t 3 gene consists of 1138 base pairs. This 
includes 105 bp long 5’ non-translated region and a open reading frame (ORF) from 
position 106-906 bp of the full length gene (Cheong et al., 2003 (b)). The IgE binding 
activity of Blo t 3 was rather weak although around 50% of the subjects selected 
reacted to it (Cheong et al., 2003 (b)). 
Not much had been done on Eur m 3 except that its mRNA sequence had been 
submitted to Gene Bank and the IUIS database (Accession number: AF047615) 
(http://www.allergen.org/List.htm, Thomas et al., 2002). 
2.4.1.4 Group 4 allergens 
Group 4 allergen was first identified in Der p (Lake et al., 1990) and Eur m 
(Mills et al., 1999). The cDNA of these allergens were subsequently identified by 
Mills et al. (Mills et al., 1999). Both Der p 4 and Eur m 4 genes coded for 496 amino 
acids and both sequences were 90% identical to each other (Mills et al., 1999).  Both 
allergens had the same calculated molecular mass: around 57000 daltons (Table 2) 
though their recombinant forms migrated on SDS-PAGE at about 60000 daltons (Mills 
et al., 1999). 
Native form Der p 4 had 46% IgE binding activity in mite-allergic adults and 
25% in allergic children (Lake et al., 1990) whereas the recombinant form (His6-
tagged) had 30% (3 / 10) (Mills et al., 1999). However, none of the 10 mite-allergic 
patients in Mills et al.’s study responded to His6-tagged recombinant Eur m 4 (Mills et 
al., 1999). 
Blo t 4 had been identified as well (Dr. Cheong Nge, personal communication) 




2.4.1.5 Group 5 allergens 
In the literature, 3 group 5 allergens have been identified so far: Der p 5, Blo t 5 
and Lep d 5 (Tovey et al., 1989; Arruda et al., 1995; Eriksson et al., 2001; Table 2).  
The molecular weight of mature Der p 5 allergen is 14000 (Tovey et al., 1989; 
Lin et al., 1994). 52% (13 / 25) of allergic subjects tested reacted positively to 
recombinant Der p 5 (expressed in E. coli system) in dot blot assay (Lin et al., 1994). 
A study in Venezuela also showed that 60% (102 / 170) allergic patients had positive 
responses in skin prick tests to recombinant Der p 5 (Lynch et al., 1997). There could 
be cross-reactivity between recombinant Der p 5 and recombinant Der p 7 (Lynch et 
al., 1997) but this requires more studies to confirm.  
Group 5 allergen identified from Blo t had 43% sequence identity with Der p 5 
(Arruda et al., 1995; Arruda et al., 1997). Blo t 5 is the only allergen identified so far 
from Blo t that is confirmed to be a major allergen. Various studies had showed the 
importance of this allergen (Arruda et al., 1995; Arruda et al., 1997; Kuo et al., 1999; 
Kuo et al., 2003; Manolio et al., 2003). To cite a few, Arruda et al. showed that 45-
70% of Blo t allergic asthmatic patients had IgE to recombinant Blo t 5 (Arruda et al., 
1995; Arruda et al., 1997), Kuo et al. showed that 91.8% (134 / 146) and 73.5%       
(36 / 49) of asthmatic subjects from Taiwan and Malaysia were positive to 
recombinant Blo t 5 (Kuo et al., 2003) and in a larger cohort study, 261 subjects (46%) 
were sensitized to Blo t 5 (Manolio et al., 2003). 
Lep d 5 was identified by Eriksson et al. using phage surface display 
technology (Eriksson et al., 2001). Recombinant Lep d 5 was recognized by 9% (4 / 45) 
Lep d positive subjects (Eriksson et al., 2001). 




2.4.1.6 Group 6 allergens 
Group 6 allergens are serine proteases and have chymotrypsin-like activity. Der 
p 6 and Der f 6 were first identified by Yasueda et al. in 1993 (Yasueda et al., 1993). 
Subsequently, Der p 6 and Der f 6 were separately cloned by Bennett et al. and 
Kawamoto et al. respectively (Bennett & Thomas, 1996; Kawamoto et al., 1999). 
Recombinant Der f 6 expressed in E. coli system was also reported (Kawamoto et al., 
1999). Der f 6 showed 75.1% sequence identity with Der p 6 (Kawamoto et al., 1999). 
Group 6 allergens in other mites have yet to be identified. Nevertheless, 
potential group 6 allergen from Blo t has been identified recently (Dr. Cheong Nge, 
personal communication, unpublished data). 
2.4.1.7 Group 7 allergens 
52% (88 / 170) of the allergic patients recruited in Lynch et al.’s study was 
positive to recombinant Der p 7 in skin prick tests (Lynch et al., 1997). Crossed RAST 
(radioallergosorbant assay) inhibition study between recombinant Der p 7 and 
recombinant Der p 5 suggested that there could be significant cross-reactivity between 
the two allergens (Lynch et al., 1997). Nonetheless, further studies were required to 
confirm this observation. 
Group 7 from Lep d has also been identified and has been shown to bind IgE 
from 62% (28 / 45) Lep d-sensitized subjects (Eriksson et al., 2001). 
2.4.1.8 Group 8 allergens 
Group 8 allergen (Table 2) from Der p was identified by O’Neill and 
colleagues (O’Neill et al., 1994). It was known as Der p 15 when originally identified 
but later classified as Der p 8 (O’Neill et al., 1994). It showed 50% identity with Yb 




77 / 193 (40%) of the mite extract sensitive subjects reacted to Der p 8 in IgE 
radioimmunoassays (O’Neill et al., 1994).  
2.4.1.9 Group 9 allergens 
Until now, only group 9 from Der p was identified and characterized (King et 
al., 1996; Table 2). Der p 9 has a molecular weight of 23780 daltons (King et al., 
1996). Functionally, it is a serine protease that could cleave collagen (King et al., 
1996). Der p 9 had a 92% IgE binding capacity in the 12 subjects selected in King et 
al.’s study (King et al., 1996). Nonetheless, larger cohort study is required to further 
confirm the high IgE binding capacity.  
There was indication that the enzymatic function of Der p 9 could also trigger a 
non-allergic inflammatory response in the airways through the release of pro-
inflammatory cytokines such as GM-CSF and eotaxin (Sun et al., 2001).  
2.4.1.10 Group 10 allergens 
Group 10 allergens are all tropomyosins (Aki et al., 1995; Asturias et al., 1998; 
Yi et al., 2002). Der f 10 (Mag44) consisted of 988 bp with an ORF of 284 amino 
acids and a molecular weight of 32954 daltons (Aki et al., 1995). Native Der f 10 
bound IgE from 90.3% (28 / 31) of mite-sensitized asthmatic subjects (Aki et al., 
1995). Nonetheless, Der p 10, though another tropomyosins from mites, had only very 
low IgE binding frequency of 5.6% only (Asturias et al., 1998). 
Yi et al. identified Blo t 10 cDNA from Blo t cDNA library recently using 
mouse anti-Der p 10 antibodies (Yi et al., 2002). The sequence was subsequently 
expressed in E. coli as a GST-fusion protein and the recombinant Blo t 10 had a 
molecular weight of around 35000 daltons in 7.5% SDS-PAGE after being cleaved 




frequency in skin prick tests (Yi et al., 2002). Lep d 10 has recently been cloned and 
characterized by Saarne et al. (Saarne et al., 2003). It consisted of 284 amino acids 
with a calculated molecular mass of 32930 daltons. Lep d 10 showed 96% sequence 
identity with Der f 10 and Der p 10. His6-tagged Lep d 10 had a molecular weight of 
33775 daltons as determined by mass spectrometry though its calculated molecular 
mass was 33752 daltons. Recombinant Lep d 10 has 13% IgE-binding frequencies 
(Saarne et al., 2003).  
2.4.1.11 Group 11 allergens 
Group 11 allergens are large proteins compared to allergens from group 1 to 10 
(Table 2). Group 11 allergen had a molecular weight of 98000 daltons (Tsai et al., 
1998 (b); Ramos et al., 2001). Group 11 allergen in Der f was identified by Tsai et al. 
while the Blo t version of it was identified by Ramos et al. (Tsai et al., 1998 (b); 
Ramos et al., 2001). Functionally, group 11 allergens are paramyosins based on 
sequence identity with paramyosins from other organisms (Tsai et al., 1998 (b); Ramos 
et al., 2001).  
Group 11 allergens had significant IgE binding capacity (Tsai et al., 1998 (b); 
Ramos et al., 2001). 87.5% (21 / 24) of mite-sensitized patients were positive to Der f 
11 in skin prick tests while 52% (33 / 63) of Blo t-sensitized subjects had IgE towards 
recombinant Blo t 11 (Ramos et al., 2001). 
2.4.1.12 Group 12 allergens 
Group 12 was only identified in Blo t until now (Puerta et al., 1996 (b)). Based 
on sequence analysis, Blo t 12 should have a mature protein of molecular weight 
14206 and a plausible 20 amino acids signal peptide (Puerta et al., 1996 (b)). The 




chitinase activity based on the fact that it had a chitin-binding domain (Stewart & 
Robinson, 2003). Blo t 12 had a 50% (16 / 32) IgE binding frequency in allergic 
asthmatics (Puerta et al., 1996 (b)). However, the prevalence and the importance of 
sensitization to Blo t 12 in the general population remain to be shown. 
2.4.1.13 Group 13 allergens 
 Three group 13 allergens had been reported in the literature: Blo t 13, Aca s 13, 
Lep d 13 (Caraballo et al., 1997; Eriksson et al., 1999; Eriksson et al., 2001). Blo t 13, 
an allergen similar to fatty acid binding proteins, was cloned and characterized by 
Caraballo et al. (Caraballo et al., 1997). Subsequently, group 13 allergens in Aca s and 
Lep d were identified by Eriksson et al. (Eriksson et al., 1999; Eriksson et al., 2001).  
In terms of IgE binding capacity, 11% (5 / 45) of allergic subjects reacted to 
Blo t 13 using RAST (Caraballo et al., 1997); 23% (3 / 13) of the subjects in Eriksson 
et al.’s study were positive to Aca s 13 (Eriksson et al., 1999); 13% (6 / 45) of Lep d-
sensitized subjects had IgE against recombinant Lep 13 (Eriksson et al., 2001). 
2.4.1.14 Group 14 allergens 
Group 14 allergens are another group of high-molecular weight allergens 
(Fujikawa et al., 1996; Epton et al., 1999). Der f 14 (originally known as Mag 3 when 
first identified and Eur m 14 have a molecular weight of 177000 daltons (Fujikawa et 
al., 1996; Epton et al., 1999). Both the native and the recombinant form of Der f 14 
could bind IgE: 70% (16 / 23) and 39% (9 / 23) of mite-sensitized asthmatic patients 
respectively (Fujikawa et al., 1996). Der f 14 and Eur m 14 had strong similarity with 




There was, however, insufficient data on Der p 14 in the literature except that it 
was listed in the IUIS database. (http://www.allergen.org/List.htm). Only partial 
sequences of Der p 14 had been described thus far (Epton et al., 1999). 
2.4.1.15 Group 15 allergens 
Group 15 allergen was only identified in Der f (McCall et al., 2001). It was one 
of the few allergens that were identified to be important in canine allergy (McCall et 
al., 2001). Der f 15, which has a predicted molecular weight of 61108 daltons, is 
considered as a high molecular weight allergen because it is highly glycosylated, 
giving it an actual molecular weight of 98000 daltons and 109000 daltons (McCall et 
al., 2001). Sequence analysis suggested that Der f 15 is a chitinase (McCall et al., 
2001). As for the allergenicity of Der f 15, 92.6% (25 / 27) Der f extract-allergic dogs 
in McCall et al.’s study had IgE against Der f 15 (McCall et al., 2001). The importance 
of Der f 15 in human allergic subjects remains to be studied.  
2.4.1.16 Group 16 
Der f 16, a gelsolin, reported by Kawamoto et al, has a predicted molecular 
weight of 55131 daltons (Kawamoto et al., 2002 (b)). The recombinant Der f 16, with 
the same molecular weight, had variable IgE binding frequencies among asthmatic 
subjects, depending on the cohort chosen: 17.9% (5 / 28) in one group of subjects and 
47% (8 / 17) in another (Kawamoto et al., 2002 (b)). 
2.4.1.17 Group 17 to 19 allergens 
Der f 17, according to IUIS database, was a calcium binding EF protein, with a 
molecular weight of around 53000 daltons (http://www.allergen.org/List.htm, Thomas 





Der f 18, an allergen homologous to chitinase, was identified in Der f by Weber 
et al. (Weber et al., 2003). It consisted of 462 amino acids, including a 25 amino acid 
signal sequence and a 437 amino acids mature protein sequence. The calculated 
molecular mass for Der f 18 was 50000 daltons. This was also one of the few allergens 
to have been shown to be allergenic to both humans and dogs (Weber et al., 2003). 
According to Weber et al., 54% of the Der f sensitized patients reacted to Der f 18 
whereas 57-77% of Der f sensitized dogs did the same (Weber et al., 2003). 
A putative anti-microbial peptide was identified by Cheong and co-workers. 
(reported in this study) and was named BtA2 originally (Lim et al., 2002). It was later 
classified as Group 19 by the IUIS Allergen Nomenclature sub-committee. 
2.4.1.18 Undesignated allergens 
Besides the 19 designated groups of allergens, there are some domestic mite 
allergens in the literature that had not been grouped (Table 2) (Aki et al., 1994; Saarne 
et al., 2003). The first one being a putative member heat shock protein (hsp) 70 family 
was identified by Aki et al. in Der f (Aki et al., 1994). The second one was a α-tubulin 
from Lep d (Saarne et al., 2003). 
2.5 Monoclonal antibodies in mite allergen studies 
The hybridoma technology was first demonstrated by Köhler and Milstein in 
1975 to be useful in the production of monoclonal antibody against antigen of interest 
(Köhler & Milstein, 1975). This technology involves the fusion of spleen cells 
(antibody producing cells (B-cells)) and myeloma cells (immortalized cells), thus 
generating a hybridoma which could produce antibody and at the same time 




became a valuable tool to generate useful reagents in everyday molecular and cell 
biology research. 
2.5.1 Applications of monoclonal antibodies in allergy studies 
Generally, monoclonal antibodies are used in identification and purification of 
allergens, epitope mapping studies and standardization of mite allergen extracts 
(Chapman et al., 1987; Luczynska et al., 1989; Härfast et al., 1992; Yunginger  & 
Adolphson, 1992; Ovsyannikova et al., 1994; Ferrándiz et al., 1995; Shen et al., 1995; 
Shen et al., 1996; Ferrándiz et al., 1997; Peng et al., 1998; Tsai et al., 2000; Labrada et 
al., 2002; Park et al., 2002; Parvaneh et al., 2002; Trombone et al., 2002; Ramos et al., 
2003). A number of native allergens (Der p 1; Der p 2; Blo t 11) have been 
immunopurified and characterized (Chapman et al., 1987; Tsai et al., 2000; Ramos et 
al., 2003). Monoclonal antibodies have also been used to identify allergens from the 
same group of allergen, for example, Eur m 2 identified by monoclonal antibody 
against Der p 2; Blo t 11 immunopurified using monoclonal antibody against Der f 11 
(Morgan et al., 1997; Ramos et al., 2003).  
ELISA-based assays developed using monoclonal antibodies for Der p1, Der f 
1, Der p 2, Lep d 2 and Der p 7 were useful in various studies: 1.) to quantify the level 
Der p 1, Der f 1, Der p 2 and Lep d 2 from dust samples (Luczynska et al., 1989; 
Ovsyannikova et al., 1994; Parvaneh et al., 2002); 2.) to detect Der f 1-specific IgE 
(Peng et al., 1998); 3.) to study the allergenicity differences of Der p 2 isoallergens 
(Park et al., 2002); 4.) epitope mapping of Der p 1, Der f 1, Der p 2 and Der p 7 
(Chapman et al., 1984; Chapman et al., 1987; Ovsyannikova et al., 1994; Shen et al., 
1996); 5.) to quantify Der p 1 and Der p 2 specific IgE (Trombone et al., 2002); 6.) to 




2.5.2 Methods in monoclonal antibody productions 
There are basically two major protocols in producing monoclonal antibodies. 
The first one was the more traditional and widely adopted method where it involved 
immunization of mice and fusion of mice spleen cells with myeloma cells to generate 
monoclonal antibody producing hybridomas while the second was relatively new 
which was derived from phage display technology (Köhler & Milstein, 1975; Smith, 
1985; McCafferty et al., 1990; Clackson et al., 1991; Marks et al., 1991).  
The widely adopted protocol for monoclonal antibody generation has not 
changed significantly since its introduction in 1975 in that it still involves the fusion 
between myeloma cells and B cells to generate antibody-producing hybridomas 
(Köhler & Milstein, 1975; Spitz et al., 1984; Svalander et al., 1987; Hong et al., 1989; 
Quak et al., 1990; Nilsson & Larsson, 1990; Barry et al., 1994; Ulivieri et al., 1996; 
Kilpatrick et al., 1997; Peet et al., 1997; Rizzuto et al., 1999; Tearina Chu et al., 2000; 
Kilpatrick et al., 2000; Velikovsky et al., 2000; Kasinrerk et al., 2002; Velikovsky et 
al., 2002; Ramos et al., 2003; Yang et al., 2003). Nonetheless, various immunization 
protocols have been introduced. These methods not only differ in the forms of antigen 
used but also in the routes of administration (Spitz et al., 1984; Svalander et al., 1987; 
Hong et al., 1989; Quak et al., 1990; Nilsson & Larsson, 1990; Barry et al., 1994; 
Ulivieri et al., 1996; Kilpatrick et al., 1997; Peet et al., 1997; Rizzuto et al., 1999; 
Tearina Chu et al., 2000; Kilpatrick et al., 2000; Velikovsky et al., 2000; Kasinrerk et 
al., 2002; Velikovsky et al., 2002; Ramos et al., 2003; Yang et al., 2003).  
In terms of the antigens used for immunization, aside from the traditional 
immunization using protein with complete Freund’s or incomplete Freund’s adjuvants, 
or with alum (Quak et al., 1990; Peet et al., 1997; Ulmer et al., 2000; Wang et al., 




of interest has also been reported (Barry et al., 1994; Attanasio et al., 1997; Tearina 
Chu et al., 2000; Kilpatrick et al., 2000; Velikovsky et al., 2000; Ramos et al., 2003; 
Wolfowicz et al., 2003; Yang et al., 2003). The incorporation of electroporation into 
DNA immunization protocol that involves intramuscular injection of plasmid DNA has 
been shown to greatly enhance the immune responses (Rizzuto et al., 1999; Widera et 
al., 2000). This was because electroporation could increase the transfection frequencies 
(Aihara & Miyazaki, 1998; Mir et al., 1999; Widera et al., 2000). The advantage of 
DNA immunization is that it enables investigators to induce antibody response in 
animals without the need to purify or generate antigen that could sometimes be 
difficult to produce or isolate (Tang et al., 1992; Costagliola et al., 1998; Moonsom et 
al., 2001; Yang et al. 2003). DNA immunization could also induce antibody responses 
when conventional immunization protocol had failed (Hong et al., 1989). On top of 
that, DNA immunization could also induce more antibodies that recognize native 
epitopes compared to immunization using recombinant protein (Attanasio et al., 1997; 
Costagliola et al., 1998). Nonetheless, the success of genetic immunization also 
depended on various other factors such as the nature of the antigen, mouse strain and 
the presence or absence of CpG motifs (Berzofsky et al., 1977; Lee & Sung, 1998; 
Chatel et al., 2003). 
Besides that, the delivery routes of antigens also affect the immune response 
(Boyle et al., 1997; Kasinrerk et al., 2002). Various routes of delivery had been 
reported, namely subcutaneous, intradermal, intraperitoneal, intramuscular and 
intrasplenic, with various degrees of success in inducing immune responses (Spitz et 
al., 1984; Hong et al., 1989; Boyle et al., 1997; Kasinrerk et al., 2002) 
The phage display method totally bypasses the immunization and fusion 




fd bacteriophage was modified to express antibody fragments on its coat and those 
phages that express antibody fragments that bind to antigen of interest could be 
enriched and selected through a process known as “biopanning” (McCafferty et al., 
1990; Clackson et al., 1991; Smothers et al., 2002). 
2.6 Antimicrobial peptides (AMPs): a brief introduction 
Antimicrobial peptides (AMPs) had been discovered in organisms from almost 
all kingdoms: from mammals, plants, to microorganisms (Papagianni, 2003). As their 
name suggests, AMPs could kill a broad range of microorganisms, which includes 
bacteria (both gram-positive and negative), fungi and even certain viruses (Gallo et al., 
2002). AMPs are important components of innate immune response as they offered the 
first-line defense against infections (Hoffmann et al., 1996; Gallo et al., 2002). 
All AMPs share a few common features: 1.) low molecular weight (below 
5000); 2.) a positive net charge at physiological pH; 3.) most had amphiphilic α-helices 
or hairpin-like β-sheets or a mixed of the two (Bulet et al., 1999). The most common 
and potent AMPs known to date could be classified as cationic peptides (Vizioli & 
Salzet, 2002). Cationic peptides could be further classified into 3 classes: 1.) linear 
peptides forming α-helices without cysteine residues; 2.) cyclic peptides with cysteine 
residues; 3.) peptides containing excessive proline and / or glycine residues (Dimarcq 
et al., 1998; Bulet et al., 1999; Vizioli & Salzet, 2002; Papagianni, 2003). Other 
groups of AMPs, classified respectively as anionic peptides, aromatic dipeptides and 
oxygen-binding proteins, in general, have weak anti-microbial properties and their 





Linear α-helix peptides 
Peptide Source Antimicrobial activity 
Cecropins Insects, pig Bacteria, fungi, virus, 
protozoa, metazoa 
Clavanin, styelin Tunicates Bacteria 
Buforins Amphibians Bacteria, protozoa 
Cyclic peptides with cysteine residues 
 α-Defensins Humans, rabbits Bacteria, fungi, virus 
 β-Defensins Cattle Bacteria, fungi, virus 
Insect defensins Insects Gram positive bacteria 
Ascaris suum antibacterial 
factor (ASABF) 
Nematode Bacteria, yeast 
Myticin Mussels Bacteria 
Mytilin B Mussels Bacteria 
MGD-1 Mussels Bacteria 
MGD-2 Mussels Bacteria 
Peptides rich with certain amino acid 
Drosocin Fruit fly Bacteria 
Metalnikowin Hemipteran Bacteria, fungi 
Bac-7 Cattle, sheep Bacteria 
Table 3: Examples of AMPs classified as cationic peptides. Examples from each 
different sub-groups (adapted from Papagianni, 2003; Vizioli & Salzet, 2002; 
Mitta et al., 2000; Mitta et al., 1999; Zhang et al., 2000; Kato & Komatsu., 1996). 
 
AMPs are produced in different manner in different organisms. Some are 
constitutively expressed, others inducible while the remaining uses both mechanisms 










3 Mite sensitization profile study 
3.1 Mite sensitization in South East Asia 
Countries in South East Asia are characterized by their tropical to subtropical 
climate with high humidity throughout the year. These climate conditions are 
especially suitable for mite growth (Arlian et al., 1998 (a-b); Chew et al., 1999 (b)). In 
fact, various studies in South East Asia had shown the high concentration of domestic 
mites (Blo t (predominant in Singapore), Der p (predominant in Thailand and Malaysia) 
in the environment (Ho, 1986; Malainual et al., 1995; Chew et al., 1999). It was also 
known that exposure to high concentration of mite allergen (≥2 µg / g of dust) 
increased the potential of sensitization in atopic individuals (Lau et al., 1989). In 
addition, the positive association of mite sensitization to allergic diseases had been 
shown (Rizzo et al., 1993; Stanaland et al., 1994; Ho et al., 1995; Droste et al., 1996; 
Ferrándiz et al., 1996; Nelson et al., 1996; Boulet et al., 1997; Leung et al., 1997; Tsai 
et al., 1998 (a); Baratawidjaja et al., 1999; Mori et al., 2001; Verini et al., 2001). 
Therefore, it is important to study the prevalence of mite sensitization in South East 
Asia using a panel of individual recombinant mite allergens. 
The prevalence of mite sensitization among allergic patients in South East Asia 
was high, ranging from 70-96% among the subjects studied (Woodcock & Cunnington, 
1980; Ho et al., 1995; Baratawidjaja et al., 1999; Chew et al., 1999 (a); Kuo et al., 
1999). The majority of the subjects in these studies were adolescents and adults who 
were suffering from allergic rhinitis and / or asthma (Woodcock & Cunnington, 1980; 




For instance, a study conducted by Ho et al. in  Malaysia  demonstrated that  82%  
(257 / 314) of the allergic rhinitis subjects were sensitized to Der p and Der f 
respectively (Ho et al., 1995). 
Most of the studies reported in South East Asia to date gave data on the 
prevalence of mite sensitization among allergic disease patients only (Woodcock & 
Cunnington, 1980; Ho et al., 1995; Baratawidjaja et al., 1999; Chew et al., 1999 (a); 
Kuo et al., 1999; Trakultivakorn & Nuglor, 2002). There was only one study on the 
prevalence of mite sensitization among the general population where it was 
demonstrated that 60.2% (193 / 321) of the randomly selected school children in Kota 
Kinabalu (situated in Sabah, Malaysia) were sensitized to Der p (Leung et al., 1997). 
This prevalence frequency was unusually high as compared to the study in Europe 
where the prevalence of mite sensitization ranged from 6.7% to 35.1% (Burney et al., 
1997). 
All the studies so far showed that mite sensitization is an important factor 
among allergic rhinitis and / or asthma patients (Woodcock & Cunnington, 1980; Ho et 
al., 1995; Baratawidjaja et al., 1999; Chew et al., 1999 (a); Kuo et al., 1999; 
Trakultivakorn & Nuglor, 2002). In order to enable better treatment, it is important to 
pin point the major sensitizing mite allergens among allergic rhinitis / asthma patients. 
This could only be done using recombinant mite allergens. 
3.2 Significance of the study 
First of all, this study was aimed at providing more information on the 
frequency of mite sensitization among allergic disease sufferers in South East Asia. 
Although there were a number of studies on the prevalence of mite sensitization in 
South East Asia (Woodcock & Cunnington, 1980; Ho et al., 1995; Leung et al., 1997; 




reagents. The usefulness of recombinant and purified domestic mite allergens as 
reagents for sensitization studies had not been fully evaluated in populations in this 
region of the world.  
Three recombinant and purified domestic mite allergens (Der p 1, Der p 2 and 
Blo t 5) had been shown to be important in both Singapore and Taiwan (Kuo et al., 
1999). Interestingly, Blo t 5 appeared to be more important among Singaporean 
subjects compared to Taiwanese subjects (Kuo et al., 1999). Nevertheless, the number 
of Singaporean subjects that were tested for their specific IgE against the three 
allergens was small in the study. More studies using larger cohorts were needed to 
further confirm these findings because Trakultivakorn & Nuglor demonstrated that Der 
p 1 and Der p 2 and not Blo t 5 were important in Thailand. It was also important to 
know whether these three allergens could potentially replace the use of mite crude 
extract. 
Therefore, in this study, the sensitization profile of rhinitis and asthma patients 
against mite crude extracts from Blo t and Der p and recombinant allergens Der p 1, 
Der p 2 and Blo t 5 were performed. This is to further compare with the findings by 
Kuo et al. (Kuo et al., 1999). At the same time, the usefulness of recombinant and 
purified domestic mite allergens sensitization study would be evaluated. 
3.3 Materials and methods 
The water used in these methods was Milli-Q water unless otherwise specified. 
3.3.1 Allergens 
3.3.1.1 Blo t and Der p mite crude extract 
Blo t and Der p mite crude extracts were prepared as described previously (Kuo 




previously (Yi et al., 1999) or lyophilized Der p (Commonwealth Serum Laboratories, 
Parkville, Australia) was homogenized in the presence of liquid nitrogen using mortar 
and pestle. Protein extraction was performed using PBS (phosphate-buffered saline) 
(for sensitization study) or TBS (Tris-buffered saline) (for purification of native 
protein), both containing 2 mM phenylmethyl-sulfonyl fluoride (PMSF) (Sigma, St. 
Louis, MO, USA) and 1 mM ethylenediamine tetraacetic acid (EDTA), pH 8.0 (Bio-
Rad, Hercules, CA, USA). The mixture was centrifuged at 15000 x g for 15 minutes 
and the supernatant was dialyzed overnight at 4 °C against 1X PBS. Protein 
concentration was determined by Bio-Rad protein assay (Bio-Rad, Hercules, CA, 
USA). The protein extracts were stored in aliquots at -80 °C. 
3.3.1.2 Preparation of Der p 1, Der p 2 and Blo t 5 allergens 
Native Der p 1 was purified from spent mite medium by affinity 
chromatography, using the monoclonal antibody 4C1 (Chapman et al., 1987). 
Recombinant Der p 2 (Chua et al., 1990; Chua et al., 1996) and Blo t 5 (Arruda et al., 
1997) were produced in the Pichia pastoris yeast expression system and purified using 
chromatographic methods (Kuo et al., 1999; Goh et al., 2001). 
3.3.2 Selection of subjects 
A total of 229 sera were obtained from randomly selected adult volunteers who 
attended a national rhinitis survey study in the ear, nose and throat outpatient clinic of 
the National University Hospital, Singapore. Out of this total, 124 subjects (62 males 
and 62 females, aged 7 - 73 years; Mean age of 34 years), were diagnosed with 
persistent rhinitis by clinician (Bousquet et al., 2001). The definition of rhinitis was 
based on the ICR algorithm recommendation for treatment of rhinitis (Lund et al., 




age: 38 years old) with no history of rhinitis were recruited for comparison. Approval 
to conduct this study was granted by the National Medical Research Council (NMRC) 
of Singapore and the institutional review board of the Medical Faculty, National 
University of Singapore.  
A total of 153 sera (94 sera from adult asthmatics (age mean age 46.4 years 
old); 49 sera from children asthmatics) visiting the asthmatic clinic in University 
Hospital, University of Malaya, Malaysia, were also included. All the patients did not 
have chronic obstructive pulmonary disease (COPD) as diagnosed by clinician. 
3.3.3 ELISA for detection of sensitization profile 
Specific IgE in the sera against Blo t 5, Der p 1 and Der p 2 were determined 
using enzyme-linked immunosorbent assay (ELISA) as previously described (Kuo et 
al). Briefly, 250 ng of allergen was coated in each well of the 96-well microtitre plate 
(Corning, NY, USA) overnight in 0.1 M NaHCO3 (Sigma, St. Louis, MO, USA). The 
plate was then washed 3 X with PBS-Tween 20 (0.05%, v/v) (washing solution) using 
Columbus washer (TECAN, Grödig, Austria). All subsequent washing steps were 
performed in the similar way. The plate was then blocked with washing solution 
containing 1% (w/v) BSA (Sigma, St. Louis, MO, USA) (blocking and dilution 
solution) for two hours. Then, the plate was washed. Sera diluted 1 : 5 in dilution 
solution was dispensed 50 µl / well and incubated overnight. The next day, the plate 
was washed and incubated with mouse anti-human IgE biotin conjugated (Southern 
Biotechnology, Alabama, USA) (1 : 2000 dilution) for 1 hour at room temperature. 
Again, the plate was washed and incubated with ExtrAvidin® alkaline phosphatase 
conjugate (Sigma, St. Louis, MO, USA) (1 : 2000 dilution) at room temperature for 1 
hr. The plate was washed and the substrate, β-Nitrophenyl phosphate (Sigma, St. Louis, 




Shell Rainbow Reader (TECAN, Grödig, Austria) at 30 minutes and 1 hour after the 
addition of substrate. 
Control sera for Singapore subjects were from a set of sera that showed 
negative results in ELISA against the allergens tested whereas control sera for 
Malaysia asthmatic subjects were from patients who gave no observable wheals to all 
the allergens in the SPT. The cut off value for individual allergen ELISA read out was 
based on the mean of all the cut offs for individual allergens of which were determined 
using the mean plus two standard deviations of these control sera against respective 
allergen. However, cut offs for mite crude extracts (Der p extract and Blo t extract) 
were determined independently from individual allergens. Their cut offs were 
determined using the mean plus two standard deviations of the ELISA readings of 
control sera to the respective extract. 
3.3.4 Skin Prick Tests (SPT) 
Skin prick tests (SPT) was performed as described previously (Chew et al., 
1999 (b)) on all the 94 Malaysian adult asthmatics. The wheal size induced by 
applying total extract of Blo t / Der p extract (Greer Laboratories Inc., Lenoir, NC, 
USA), allergens Blo t 5, Der p 1 or Der p 2 on the forearm (pricking site) was 
considered positive if its diameter was larger than 3 mm after 30 minutes (Chew et al., 
1999 (b)). Histamine (1 mg / ml) and PBS were used as positive and negative control 
respectively. All subjects were requested not to take antihistamines for 24 hours before 
SPT was performed. 
3.3.5 Computer-aided statistical analysis 
The OD405nm readings from Singapore subjects were analyzed using Mann 




(non-parametric methods) was chosen because it required fewer assumptions on the 
population where the data was derived. Correlation coefficients and odds ration 






3.4.1 Sensitization profile of Singapore subjects 
In this study we have determined the dust mite allergens sensitization profile 
for four subgroups of subjects: rhinitis and non-rhinitis subjects from Singapore; adults 
and children with asthma from Malaysia. 
The sensitization profile of rhinitis subjects to the domestic mite allergens used 
in this study was as follow: Blo t extract +: 91 / 124 (73%); Blo t 5 +: 62 / 124 (50%); 
Der p extract +: 61 / 124 (49%); Der p 1 +: 53 / 124 (43%); Der p 2 +: 45 / 124 (36%).  
The non-rhinitis subjects’ sensitization profile was as follows: Blo t extract +: 60 / 105 
(57%); Blo t 5 +: 24 / 105   (23%); Der p extract +: 38 / 105 (36%); Der p 1 +:           
14 / 105(13%); Der p 2 +: 17 / 105 (16%). 
There were significant differences in the levels of allergen specific IgE in 
rhinitis versus non-rhinitis subjects. In fact, the rhinitis subjects generally had a higher 
titre of IgE (inferring from higher OD reading) than non-rhinitis subjects (Figure 3). In 
addition, a higher number of rhinitis subjects were sensitized to each of the allergens 
compared to non-rhinitis group. In the rhinitis cohort, 81 / 124 (65%) reacted to at least 
one allergen from Blo t and / or Der p (Blo t 5 / Der p 1 / Der p 2), while in the non-





Figure 3: Allergen specific IgE titre from rhinitis (R) (n=124) and non-rhinitis 
(NR) (n=105) subjects from Singapore.  Significant differences were observed 
between the two groups for all allergens when analyzed using Mann Whitney 
statistical analyses. “*” means significant difference was observed. Ext = Extract; 
Bt = Blo t; Dp = Der p.   Cut off = 0.093 for Der p 1, Der p 2, Blo t 5; cut off = 
0.101 for Blo t extract; 0.090 for Der p extract. 
 
   A        B 
Figure 4: Sensitization profile of Singapore rhinitis (A) and non-rhinitis (B) 
subjects based on ELISA results. Cut off = 0.093 for all allergens in both diagram 





Correlation between the single allergens among rhinitis subjects was: Der p 1 – 
Der p 2: r = 0.60; Blo t 5 – Der p 1: r = 0.64; Blo t 5 – Der p 2: r = 0.78. Correlation 
for the same parameters for non-rhinitis: Der p 1- Der p 2: r = 0.71; Blo t 5 – Der p 1: r 
= 0.51; Blo t 5 – Der p 2: r = 0.45. 
 Odds Ratio (95% confidence interval) 
Blo t Extract 2.1 (1.2, 3.6) 
Blo t 5 3.4 (1.9, 6.0) 
Der p Extract 1.7 (1.0, 2.9) 
Der p 1 4.9 (2.5, 9.4) 
Der p 2 2.9 (1.6, 5.6) 
Table 4: The association of sensitization to various domestic mite allergens with 
rhinitis patients. 
  
 Odds Ratio (95% confidence interval) 
Mite sensitization (MS) 2.2 (1.1, 4.3) 
MS (Der p 1, Der p 2, Blo t 5) 3.6 (2.1, 6.2) 
MS (extracts alone) 1.9 (1.1, 3.5) 
Table 5: The association of overall mite sensitization to rhinitis. 
 
As shown in Table 4, all the allergens used were associated with rhinitis. This 
indicated that for example, if one was sensitized to Blo t 5, he / she had 3.4 times 
higher chance of having rhinits (Table 4). All allergens except for Der p extract, 
generally were associated with increase chance of suffering from rhinitis, judging from 
the 95% confidence interval (Table 4). The associations of Der p 1 and Blo t 5 
sensitizations to rhinitis were the strongest (Table 4). Taken together, mite 
sensitization status determined solely using Der p 1, Der p 2 and Blo t 5 had higher 





3.4.2 Sensitization profile of Malaysian patients with asthma 
Our study on Malaysian adult with asthma showed that 39% of the adult 
patients with asthma were sensitized to Der p 1; 32% to Der p 2; 37% to Blo t 5 based 
on ELISA results. The corresponding sensitization profiles in the asthmatic children 
were 57% to Der p 1, 39% to Der p 2 and 90% to Blo t 5 (Figure 5). Due to the fact 
that the number of subjects in both the adult and the children cohorts were relatively 
small, no statistical tests were performed to compare the significance of the differences 
between the two groups. SPT results coincided quite well with ELISA results, as 
shown by the few individuals that were detected only by either tests but not both 
(Table 6). 
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Figure 5: Sensitization profile of adult (A) and children patients with asthma (B) 
from Malaysia based on ELISA results. Cut off = 0.15 for all allergens in both 











N=94 Der p 1 Der p 2 Blo t 5 
SPT + 33 (35%) 32 (34%) 30 (32%) 
ELISA + 39 (41%) 32 (34%) 37 (39%) 
ELISA +; SPT + 24 (26%) 25 (26%) 27 (29%) 
Table 6: Comparison of Malaysia asthmatic adults’ skin prick tests (SPT) and 
ELISA results from Malaysian adults with asthma. 
 
Considering SPT results alone, 36 / 94 (38%) of the Malaysian adults with 
asthma were positive to Der p extract while 32 / 94 (34%) were positive to Blo t 
extract, both of which were quite similar to the results obtained from using individual 
allergens (Table 6). 18 / 36 (50%) of the Der p extract positive subjects were also 
positive to Der p 1 and Der p 2 SPT. In addition, 6 / 36 (17%) were positive to Der p 1, 
4 / 36 (11%) were positive to Der p 2. In other words, 28 / 36 (78%) Der p extract 
(SPT) positive subjects could be accounted for by combining Der p 1 and Der p 2 SPT. 
On the other hand, Blo t 5 SPT managed to detect 22 / 32 (69%) of the Blo t extract 
positive (SPT) subjects. 
Besides, the correlation between Der p 1 and Der p 2 sensitization was 0.77 for 
adult asthmatics, 0.94 for children. There was less correlation between Blo t 5 
sensitization and either Der p 1 or Der p 2 (Blo t 5 – Der p 1 (adult) = 0.47, (children) 
= 0.22; Blo t 5 – Der p 2 (adult) = 0.41, (children) = 0.27). The slightly higher 
correlation between Blo t 5 and Der p 2 could be due to the possibility that both mite 
allergens were important early sensitizing agents. 
The other interesting observation in this study was the frequency of multi-
allergen sensitization in the asthma and rhinitis populations (Figure 4; Figure 5). 
However, certain individual allergen had higher frequency of sensitization than other. 
For instance, a majority of the patients were sensitized to Blo t 5. This was true for 






3.5.1 Sensitization profile of Singapore subjects 
 
Our study on Singaporean subjects showed that a high percentage of the rhinitis 
patients were sensitized by both Der p and Blo t mites. These subjects showed 
sensitivity to at least one major allergen from Blo t and Der p mites (Figure 4). Our 
results also revealed that 34% of the non-rhinitis subjects were also sensitized by 
domestic mite allergens (Figure 4). The data suggest that mite sensitization in our 
general population is highly prevalent and that allergen sensitization does not always 
lead to clinical symptoms implying that the relevance of serum IgE to disease 
prediction remains controversial (Burrows et al., 1989; Smith, 1992; Hogan et al., 
1997; Lynch et al., 1998; Niederberger et al., 2001). For instance, Burrows et al. 
(Burrows et al., 1989) reported that serum IgE could be predictive of rhinitis and 
asthma, on the contrary others (Hogan et al., 1997; Hogan et al., 1998) have shown 
that experimental asthma phenotype could be independent of IL-4 and allergen specific 
IgE. The correlation of allergen-specific IgE with the severity of allergic symptoms has 
also been shown to be weak (Niederberger et al., 2001). 
Although our study showed that generally rhinitis subjects had higher allergen-
specific IgE levels compared to non-rhinitis (Figure 3), allergen-specific IgE in serum 
is not the only indicator for allergic diseases as suggested by other investigators (Smith, 
1992; Burrows et al., 1995; Droste et al., 1996). Therefore diagnosis by trained 
clinicians is still highly desirable (Smith, 1992). However, patients’ sensitization 
profile can serve as helpful information in the diagnosis of rhinitis. This is because the 
odds of a rhinitis subject being sensitized to any of the three allergens used is generally 
greater than in non-rhinitis (Table 5). The association of mite sensitization with rhinitis 




both pollen and house dust sensitization (Gergen & Turkeltaub, 1992; Boulet et al., 
1997; Plaschke et al., 2000). Nonetheless, it should also be noted that antigen-specific 
IgE is not the most important causing factor in allergic rhinitis or allergic asthma. TH2 
cell and cytokine signalling pathways play a major role in the pathogenesis of allergic 
diseases (Corry, 2002). The production of antigen-specific IgE could be an important 
indication in the early stage of disease but not in the later stage.  
3.5.2 Sensitization profile of Malaysian patients with asthma 
The sensitization profile of Malaysia asthmatic adults, as determined by ELISA, 
was quite different to that of children asthmatics, especially with respect to Blo t 5 
sensitization (Figure 5). This observation was probably attributed by the age factor 
(Boulet et al., 1997). Influence of age on IgE responsiveness to domestic mite 
allergens had been reported (de Groot et al., 1990; Shibasaki et al., 1994; Boulet et al., 
1997). Though the frequency has decreased, it is still quite high in adults.  Although 
this observation was in contrary to the report that sensitization actually increased with 
age (Gerritsen et al., 1990), it was in good accordance with the observation by 
Burrows et al. where they showed that serum IgE levels decline significantly with age 
among patients with asthma (p<0.0001) (Burrows et al., 1989). Furthermore, Boulet et 
al. also showed that allergen sensitization among older adults (>46 years old) was 
much lower than that of age group 6-15 years (Boulet et al., 1997). An earlier report by 
de Groot et al. also showed that children below age of four had a higher sensitization 
frequency towards domestic mites allergens and animal danders (de Groot et al., 1990). 
These could probably help to explain our observation because the age of adult patients 
with asthma in our study was generally skewed towards middle age rather than in the 




diagnosed asthma, and were not complicated with COPD which could have 
complicated the interpretation of the data (Dow, 1998). 
The sensitization profiles of Malaysian children with asthma observed in this 
study revealed that sensitization to Blo t 5 allergen was as high as 90%, and 
sensitization to Der p 1 was 57%. The data are in good accordance with results 
previously reported by Leung et al. (Leung et al., 1997). It was shown that the 
frequency of positive skin prick test reactivity of older children (age range 12-18 years) 
in the general population from Kota Kinabalu, Sabah, Malaysia to Der p extract was 
about 60%. An interesting observation from another study was that allergic subjects 
having both asthma and rhinitis had significantly higher reactivity to Der p 5 compared 
to groups suffering from either of the diseases (Lin et al., 1994). Whether the asthmatic 
children in our study were also suffering from rhinitis were not noted. Therefore, we 
could only speculate that it might be the special properties of group 5 allergens that 
caused these observations (although previous study has demonstrated low 
crossreactivity between Blo t 5 and Der p 5) (Kuo et al., 2003). 
Another worth noting observation in this study was that the sensitizations to 
Der p 2 were below 50% in both Singapore and Malaysian subjects. Our study 
coincided well with similar study conducted by other investigators in Thailand where 
they observed less than 50% sensitization to Der p 1, Der p 2 and Blo t 5 
(Trakultivakorn & Nuglor, 2002). Nonetheless, this was rather surprising as the 
previous epidemiological study indicated that the extremely high number of both Der p 
and Blo t mites were found in Singapore homes (Chew et al., 1999 (b)) and the levels 
of Blo t and Der p allergens found in these homes were very high (Zhang et al., 1997).  
This result also showed discrepancy with other published studies in which it was 




Der p 2 (Tsai et al., 2000) or Blo t 5 (Manolio et al., 2003). Therefore, further studies 
are required to fully address this discrepancy if the observed phenomenon was unique 
to this region of the world.  
Although in general ELISA and SPT results did coincide, discrepancies did 
occur too (Table 6). This was rather expected because of the differences in nature of 
both tests (Smith, 1992). Besides that, the cut off for allergen-specific IgE in in vitro 
assays is still debatable (Bernstein & Storms, 1995). In relation to this issue, borderline 
cases could be misclassified as either positive or negative depending on the cut off 
value used (Homburger & Jacob, 1982).  
 
3.5.3 Implications  of  mite  sensitization  in  allergic  rhinitis   and   
allergic  asthma 
 
The association between mite sensitization and rhinitis was quite clear (Table 4, 
Table 5). Although similar analysis was not performed on allergic asthma subjects due 
to the lack of enough normal subjects for comparison, it would be expected that the 
association does occur as well for allergic asthma. The association of mite sensitization 
to allergic diseases has several implications. The first one being that it could be 
possible to reduce the symptoms of allergic diseases in patients by implementing 
allergen avoidance measures (Eggleston & Bush, 2001). The second would be 
allergen-avoidance among non-sensitized subjects could potentially reduce their 
chance of developing allergic diseases later in life. Nevertheless, the effectiveness of 





3.5.4 Component-resolved diagnosis of mite sensitization 
Component-resolved diagnosis (Valenta et al., 1999 (a)) of mite sensitization 
allows the identification of the major sensitizing mite allergens of a patient. 
Conventional crude mite extract could only indicate that whether one is sensitized to 
mite but could not pin point the exact allergen in the mite extract that causes the 
sensitization (Valenta & Kraft, 1995). Moreover, it is difficult to standardize the 
quality of the crude mite extract (Yunginger & Adolphson, 1992). 
The individual allergens (Blo t 5, Der p 1, Der p 2) used in this study provided 
valuable insight into the mite sensitization profile of allergic rhinitis and allergic 
asthma subjects. It shows that Blo t 5 is a very important sensitizing agent in both 
disease groups (Figure 4; Figure 5). Between Der p 1 and Der p 2, it seems that Der p 2 
is more important (Figure 4; Figure 5). It is possible that both Blo t 5 and Der p 2 are 
important early sensitizing allergens. This information can never be obtained using 
crude mite extract alone. 
With the identification of the sensitizing allergens, it is then possible to perform 
component-resolved immunotherapy on these patients (Valenta et al., 1999 (a)). 
3.6 Conclusion and future direction 
In summary, our study confirms the results of a previous study (Kuo et al., 
1999) that Der p 1, Der p 2 and Blo t 5 are important sensitizing allergens among the 
Singapore and Malaysian subjects. Besides, we also demonstrated the association 
between mite sensitization and rhinitis. For the Malaysian patients with asthma, 
sensitization to these three mite allergens was much more prevalent in children as 
compared to the adult counterparts. The three allergens are important reagents for 




Future studies using recombinant and purified allergens should include allergic 
disease patients from other parts of South East Asia like Thailand, Indonesia, Vietnam, 
Myanmar, so as to give a better picture of the sensitization profile of allergic subjects 
in this region. Apart from that, the importance of Der p 1, Der p 2 and Blo t 5 in this 
part of the world could also be further established. 
In this study, we did not look at the frequency of asthmatic symptoms among 











4 Cloning of a unique allergen from Blomia tropicalis and 
monoclonal antibody production 
4.1 Objectives and significance of the study 
This study contributed to the effort of identifying a complete spectrum of 
allergens from Blo t by identifying a unique allergen, Blo t 19, from Blo t via cDNA 
library screening. 
Monoclonal antibody was proven to be useful in purifying native allergens 
from mite crude extracts (Tsai et al., 1998 (b); Ramos et al., 2003; Yang et al., 2003). 
Therefore, it was hoped that by generating monoclonal antibody against Blo t 19, its 
native form could be isolated. 
A monoclonal antibody was successfully raised against Blo t 19. This 
monoclonal antibody was useful in western blot and ELISA. 
Aside from the main objectives, this study also further proved the observation 
that different mouse strain and the nature of individual mite allergen could influence 















Primer name 5’ Primer sequence 3’ 
BspE1-Bt19 AAT CCGGA GCT CTC GAC TTT ACC AGC TGT 
Bt19-Not I ATA AGA ATG CGG CCG CTT AAC CCC TGG AGG GCA GAT T 
M13 Forward (-20) GTA AAA CGA CGG CCA G 
M13 Reverse CAG GAA ACA GCT ATG AC 
pC1NeoF TTAATACGACTCACTATAGG 
pC1NeoR CATTAACCCTCACTAAAGGG 
Table 7: Primers used in this chapter. Underlined sequences are the restriction 
enzyme sequences introduced. All primers were purchased from Proligo 
Singapore Pty Ltd. 
4.2.1.2 Kits 
The following commercial kits were used: Wizard® Lambda Preps DNA 
Purification System kit (Promega, Madison, USA), QIAGEN Plasmid Giga, 
QIAquick® Gel Extraction Kit (QIAGEN, Hilden, Germany), DIG High Prime DNA 
Labeling and Detection Starter Kit II (Roche, Diagnostics, Manheim, Germany), 
PUREGENE™ DNA Purification Kit (Gentra Systems, Minneapolis, MN, USA),  
Pichia expression kit, TOPO-TA Cloning Kit (Invitrogen, Carlbad, CA, USA), Quick 
Ligation Kit (New England Biolabs Inc., Beverly MA, USA),  ClonaCell™-HY 
Hybridoma Cloning Kit (StemCell Technologies Inc., Vancouver, Canada).  
4.2.1.3 Centrifugations 
All centrifugations were carried out in a table top centrifuge (Eppendorf 
Centrifuge 5415, Eppendorf AG, Hamburg Germany) unless otherwise specified. 
4.2.1.4 Serum samples 
Sera from 4 adults who showed positive skin prick test reaction to Blomia 




library (4.2.2). 20 sera from candidates with positive skin prick test to Blo t extract 
were also chosen for IgE reactivity study (4.2.2.2). Another 22 sera (12 rhinitis patients, 
10 healthy subjects) were also used to test the allergenicity of Blo t 19. 
4.2.2 Identification of Blo t 19 
4.2.2.1 Screening of λgt11 expression library of Blomia tropicalis 
 
Library screening was performed by plaque IgE immunoassay. This cDNA 
library was generated from the local Blomia tropicalis mites. The pooled sera was 
adsorbed with lysate prepared from E. coli (Y1090) and recombinant E. coli containing 
GST-Blo t 5 overnight at 4°C on an orbital rotator before use. Phages were plated at 5-
10,000 plaque-forming units (pfu) per 145 mm NZY agar plate (Appendix A). Plaques 
were transferred to nitrocellulose filters (Amersham Biosciences, Buckinghamshire, 
England) that were saturated with isopropyl-β-D-thiogalactopyranoside(IPTG). This 
was done by overlaying the IPTG treated filters on the growing plaques, and then 
incubating at 30°C for an hour in an incubator. The filters were then removed from the 
agar plate and after blocking the filters with 5% solution of skim milk powder for 1 
hour, they were then washed three times with PBS-Tween 20 (0.05%, v/v) (washing 
solution), followed by overnight incubation with sera (1:1 dilution in washing solution 
containing 1% skim milk and 0.02% sodium azide) at 4°C. These filters were again 
washed three times. They were then incubated with the monoclonal anti-human IgE 
alkaline phosphatase conjugated (1:1,000 dilution) (Pharmingen, San Diego, CA, USA) 
for an hour at room temperature followed by three washes in buffer. After the last 
wash the filter was blotted on paper towels and then incubated in developing solution 
containing 5-bromo-4-chloro-3-indolyl phosphate (BCIP, Sigma) and nitro blue 
tetrazolium (NBT, Sigma), for half to an hour. An intense bluish purple colour reaction 




was subjected to several additional rounds of plating and screening to obtain a pure 
single plaque.  
 
4.2.2.2 Human IgE reactivity of Blo t 19 clone of Blomia tropicalis  
 
Individual serum from each candidate was treated as described in section 4.2.2 
for pooled sera. A positive clone designated as Blo t 19 gt11 clone was plated at 
approximately 1,000 pfu per 145 mm NZY agar plate (Appendix A) and treated as 
previously described (4.2.2).  Sera from 20 Blo t extract sensitized subjects were tested. 
4.2.2.3 Isolation of DNA from the positive λgt11 cDNA clone, Blo t 19 
 
Phages from immuno-positive plaques were amplified by the liquid lysate 
method. DNA was isolated using the Wizard® Lambda Preps DNA Purification 
System kit (Promega, Madison, USA) according to the manufacturer’s instructions. 
4.2.2.4 Polymerase chain reaction (PCR) amplification of phage clones 
 
Approximately 40-60 ng of DNA was added in a 25 µl reaction mixture 
containing 0.4 pmol of λgt11 forward and reverse primers, 0.2 mM of dNTPs, 1 U of 
Native pfu DNA polymerase, 2.5µl of 10X Native Pfu DNA polymerase buffer 
(Stratagene, La Jolla, CA, USA). Forty cycles of amplification was performed using a 
GeneAmp PCR System 2400, Perkin Elmer. Each cycle consists of 95°C for 1 minute 
30 seconds, 65°C for 1 minute 30 seconds and 72°C for 2 minutes. The PCR DNA was 
further purified using QIAquick® Gel Extraction Kit (QIAGEN, Hilden, Germany) 






4.2.2.5 QIAquick® Gel Extraction Kit (QIAGEN, Hilden, Germany) 
 
DNA was further purified using QIAquick® Gel Extraction Kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s protocol. Briefly, the DNA 
fragment was excised from the agarose gel and dissolved in 1 gel volume of Buffer QC 
at 50ºC for 10 minutes. After dissolving the gel, 1 gel volume of isopropanol was 
added and transferred to a QIAquick spin column in a 2.0 ml collection tube. The 
column was centrifuged at top speed for 1 minute. Flow-through was discarded and 
0.75 ml of Buffer PE added to the column. The column was then centrifuged again 
with the same parameters as before. The flow-through was again discarded and the 
column was centrifuged for further 1 additional minute to remove the traces of PE 
buffer. 
After that, the QIAquick column was transferred to a clean microcentrifuge 
tube. DNA was eluted by adding 30-50 µl of Milli-Q water to the centre of the 
QIAquick column and the column was then centrifuged at top speed. 
4.2.2.6 Sequence Analysis 
 
The deduced nucleotide sequence of Blo t 19 was submitted to the databases of 
the National Center for Biotechnology Information (NCBI), using the BLAST network 
server for sequence and amino acid homology search. Blo t 19 was subsequently 
cloned into E. coli (pGEX4T1-Blo t 19) and in yeast for recombinat protein 








4.2.2.7 Southern blot analysis 
4.2.2.7.1 Probe generation 
Blo t 19 gene was released from pGEX4T-1-Blo t 19 plasmid using BamHI and 
EcoRI restriction enzymes. The gene was gel purified from 1% agarose gel as 
described previously (4.2.2.5). 
4.2.2.7.2 Probe labeling 
The Blo t 19 DNA probe was labeled using DIG High Prime DNA Labeling 
and Detection Starter Kit II (Roche, Diagnostics, Manheim, Germany) according to the 
manufacturer’s recommendations. In brief, 1 µg of purified Blo t 19 gene, diluted to a 
total volume of 16 µl in ddH2O, was heat denatured in boiling water bath for 10 
minutes and immediately chilled on ice. To each reaction, 4 µl of the DIG-High Prime 
(Roche Diagnostics, Mannheim, Germany) was added, gently mixed, and incubated at 
37ºC for 14 to 16 hours. Two microliters of 0.2 M Disodium 
ethylenediaminetetraacetate (EDTA) (BioRad, Hercules, CA, USA), pH 8.0, were 
added to each reaction tube to terminate the labeling reaction. The reaction was heated 
for 10 minutes at 65°C after the addition of EDTA.  
4.2.2.7.3 Isolation of mite genomic DNA 
Genomic DNA purification was carried out according to the manufacturer’s 
recommendation (PUREGENE™ DNA Purification Kit, Gentra Systems, Minneapolis, 
MN, USA). Briefly, 50-100 mg of frozen mites (Blo t or Der f) were homogenized 
thoroughly using 30-50 strokes of tube pestle in 3 ml of Cell Lysis Solution. The lysate 
was then incubated at 65ºC for 60 minutes and mixed by inverting 25 times or until 
tissue particulates have dissolved. 1.5 µl of RNase A Solution (4 mg / ml) was added to 




After that, the samples were cool to room temperature before 100 µl of Protein 
Precipitation Solution was added. The mixture was vortexed vigorously at high speed 
for 20 seconds followed by centrifugation at top speed (Jouan Centrifuge BR4i) for 3 
minutes and the supernatant was transferred to a clean 1.5 ml microfuge tube 
containing 300 µl of 100% isopropanol. The mixture was mixed by inverting gently for 
50 times followed by centrifugation at top speed for 5 minutes. Supernatant was 
removed and the DNA pellet washed by adding 300 µl of 70% ethanol. Then, 
centrifugation was again carried out at top speed for 1 minute at 4ºC. The supernatant 
was aspirated dry and the pellet air-dried for 10-15 minutes before being dissolved in 
50 µl of DNA Hydration Solution for 1 hour at 65ºC. The DNA was stored at -20ºC 
until use. 
4.2.2.7.4 Hybridization and detection 
Hybridization and detection was carried out according to the manufacturer’s 
recommendation (DIG High Prime DNA Labeling and Detection Starter Kit II (Roche, 
Diagnostics, Manheim, Germany)). Mock hybridization (hybridizing empty 
membranes with different concentrations of probe) was carried out to determine the 
optimum probe concentration for hybridization. 
4.2.2.8 Allergenicity of GST-Blo t 19 
ELISA was performed as described in section 3.3.3 with the following 
modifications: sera (1:5 dilution) was tested against GST-Blo t 19 and Glutathione S-
transferase (GST). Sera from 12 Blo t extract sensitized rhinitis subjects were tested. 
The cut off value was derived from mean plus two standard deviations of readings 








































Figure 6: Flow chart of the cloning strategy employed in this chapter. Note: PCR: 
polymerase chain reactions; RE: restriction enzyme; Bt19: Blo t 19. RE digestion 
was performed using BspE1 and Not I restriction enzymes. Primers used to 
amplify Blo t 19 gene from pGEX4T-1-Bt19 were BspE1-Bt19 and Bt19-Not I 
(Table 7). 
 The cloning processes of Blo t 19 gene into pC1Dp5L vector were shown in 
Figure 6. 
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4.2.3.1 Cloning of Blo t 19 from pGEX4T-1 to pCR2.1 (TOPO vector) 
BspE1 and Not I restriction enzyme cutting sites were introduced at the 5’ and 
3’ end of the Blo t 19 gene amplified from pGEX4T-1-Bt19 plasmid using BspE1-
Bt19 and Bt19-Not I as primers (Table 7) in PCR (Figure 6). PCR products were 
analyzed on 1% agarose gel electrophoresis and purified using QIAquick® Gel 
Extraction Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol 
(4.2.2.5).  
Cloning was performed according to the manufacturer’s recommendations 
(Invitrogen, Carlbad, CA, USA). Briefly, a TOPO cloning reaction (6 µl) which 
consisted of 2 µl of fresh PCR product, 1 µl salt solution, 2 µl of sterile Milli-Q water 
and 1 µl of TOPO vector (Appendix B), was set up. The mixture was gently mixed and 
incubated for 30 minutes at room temperature (~25°C). After that, the reaction mixture 
was placed on ice and transformed into competent cells using Top 10 One Shot 
Chemical Transformation protocol (4.2.3.2). 
4.2.3.2 Top 10 One Shot Chemical Transformation 
The protocol was performed according to the manufacturer’s recommendation 
(Invitrogen, Carlbad, CA, USA). Briefly, 2 µl of the TOPO reaction was added into a 
vial of One Shot Chemically Competent Escherichia coli (Invitrogen, Carlbad, CA, 
USA) and mixed gently. The mixture was incubated on ice for 30 minutes, followed by 
30 seconds of heat shock in 42°C water bath, and placed on ice again. Then, 250 µl of 
room temperature SOC medium was added. The tube was capped tightly and incubated 




spread onto selective plate and incubated overnight at 37°C. The next day, white 
colonies (positive) were picked for analysis. 
4.2.3.3 Cloning of Blo t 19 from TOPO vector into pC1Dp5L vector 
pC1Dp5L vector was chosen based on similar experiment as previously 
decribed by Yang and colleagues (Yang et al., 2003). It was shown that with pC1Dp5L 
vector carrying the Blo t 3 gene was able to induce immune response in mice which 
subsequently enabled Blo t 3-specific monoclonal antibody to be produced (Yang et al., 
2003). 
Blo t 19 gene was released from TOPO vector using BspE1 (New England 
Biolabs Inc., Beverly MA, USA) and Not I (Promega, Madison, USA) restriction 
enzymes. Then, Blo t 19 gene was ligated into BspE1 and Not I digested pC1Dp5L 
vector (Appendix B) using Quick Ligation Kit (New England Biolabs Inc., Beverly 
MA, USA) according to the manufacturer’s instruction. 
Briefly, 50 ng of vector was combined with a 3-fold molar excess of insert in a 
total of 10 µl reaction mixture (top up with Milli-Q water). 10 µl of 2X Quick Ligation 
Buffer (New England Biolabs Inc., Beverly MA, USA) was added and mixed. Then, 1 
µl of Quick T4 DNA Ligase (New England Biolabs Inc., Beverly MA, USA) was 
added and mixed thoroughly. The reaction was then centrifuged briefly and incubated 
at room temperature (25°C) for 5 minutes, followed by chilling on ice and transformed 
according to manufacturer’s recommendation. 
50 µl of competent cells was added to 2 µl of chilled ligation mixture in a      
1.5 ml microcentrifuge tube, mixed by pipeting up and down, and incubated for 30 
minutes. After that, the mixture was subjected to heat shock for 2 minutes at 37°C and 




incubated for 37°C for one hour. Next, 100 µl of the mixture was spread onto LB agar 
plate containing ampicillin (CalBioChem®, EMD Biosciences, Inc., San Diego, CA, 
USA) and incubated overnight at 37°C. 
4.2.3.4 Polymerase chain reactions (PCR) 
Polymerase chain reactions (PCR) were carried out in thermal controller (PTC-
100™ programmable thermal controller, MJ Research Inc.).  A typical PCR reaction 
was as follow: 
Components Volume (µl) 
Milli-Q water 17.25 
10X buffer 2.5 
25 mM MgCl2 1.5 
Forward primer (10 pmol / µl) 1.0 
Reverse primer (10pmol / µl) 1.0 
10mM dNTPs 0.5 
Mix well, followed by short centrifuge 
Taq polymerase 0.25 
DNA template 1.0 
Total 25.0 
Table 8: Typical PCR reaction used in the study. Forward primer was BspE1-
Bt19 (Table 7) and reverse primer was Bt19-Not I (Table 7). 
 
 Each cycle of PCR consisted of 94°C for 15 seconds followed by 55°C for 30 
seconds followed by 72°C for 1 minute. Thirty cycles were carried out with a final 











4.2.3.5 DNA sequencing 
Typical PCR reaction set up was as follow: 
Components Volume (µl) 
Milli-Q water 10.0 
Big Dye ® sequencing mix (Applied 
Biosystem, Foster City, CA, USA) 
8.0 
Forward / Reverse primer (10 pmol / µl) 1.0 
DNA template 1.0 
Total 20.0 
Table 9: Typical PCR reaction used in this study for sequencing (according to 
manufacturer’s recommendation). Forward primer was M13 forward (-20) 
(Table 7) and reverse primer was M13 reverse (Table 7) for sequencing TOPO 
clones. For sequencing pC1Dp5L-Bt19 clones, pC1NeoF (Table 7) and pC1NeoR 
(Table 7) was used as forward and reverse primers. 
Each cycle of PCR consisted of: 96°C for 30 seconds, 50°C for 15 seconds and 
followed by 60°C for 4 minutes. The reaction was subjected to 26 times of this cycle. 
Reactions were carried out in thermal controller (PTC-100™ programmable thermal 
controller, MJ Research Inc.). 
4.2.3.6 Ethanol precipitation  
Two microliters of 3 M sodium acetate, pH 4.6, and 50 µl of cold absolute 
ethanol were added to the PCR product. The mixture was vortexed and placed on in     
-80°C freezer for 15 minutes prior to centrifugation at 14,000 rpm using a tabletop 
centrifuge, 5415C (Eppendorf, Hamburg, Germany) for 20 minutes at 4°C. The ethanol 
was aspirated with a micropipettor and the pellet, rinsed with 250 µl of 70% pre-cooled 
ethanol and centrifuged as mentioned. Then, the ethanol was aspirated and the pellet 
was air-dried.  
4.2.3.7 Alignment 
All alignment of sequences was performed using Clustal W Multiple Sequence 




4.2.3.8 Large scale preparation of pC1Dp5L-Bt19 DNA for injection 
pC1Dp5L-Bt 19 plasmid was prepared in large scale using QIAGEN Plasmid 
Giga (QIAGEN). Briefly, single colony picked from freshly streaked selective plate 
was used to inoculate a starter culture of 10 ml LB broth medium (Appendix A) 
containing the ampicillin (CalBioChem®, EMD Biosciences, Inc., San Diego, CA, 
USA). The culture was incubated for around 8 hours at 37°C with vigorous shaking 
(~300 rpm), after which the culture was diluted 500 to 1000 times into 2.5 litres of 
selective LB medium and grown at 37°C for 12-16 hours with vigorous shaking 
(~300rpm). The bacterial cells were harvested by centrifugation at 6000 x g for 15 
minutes at 4°C. Then, the bacterial pellets were resuspended in 125 ml of Buffer P1, 
followed by 125 ml of Buffer P2. The mixture was mixed gently by inverting 4-6 times, 
and incubated at room temperature for 5 minutes. After that, 125 ml of chilled Buffer 
P3 was added and the mixture mixed immediately but gently by 4-6 times of inversion 
and incubated on ice for 30 minutes. After incubation, the mixture was centrifuged at 
≥20,000 x g for 30 min at 4 °C. Supernatant containing plasmid DNA was removed 
promptly and re-centrifuged at ≥ 20,000 x g for 15 minutes at 4°C. Supernatant 
containing plasmid DNA was removed promptly and loaded to pre-equilibrated 
QIAGEN-tip 10000 column (equilibrated by passing 75 ml of buffer QBT through the 
column via gravity flow). The QIAGEN-tip was then washed with a total of 600 ml 
buffer QC. DNA was eluted with 75 ml Buffer QF.  
DNA was precipitated by adding 52.5 ml (0.7 vol) room-temperature 
isopropanol (Merck) to the eluted DNA. The mixture was then mixed and centrifuged 
immediately at ≥15000 x g for 30 minutes at 4°C. The supernatant was decanted 
carefully. DNA pellet was washed with 10 ml of room temperature 70% ethanol, and 




disturbing the pellet. The pellet was air-dried overnight, and redissolved in a suitable 
volume of sterile 1X PBS. 
4.2.4 Monoclonal antibody generation 
4.2.4.1 Mice 
Six to eight weeks old female Balb/c, Balb/cJ, AKR, CBA, C57/B6 mice kept 
under conventional conditions were used for the various experiments in this chapter. 
Five mice per group were typically used for monoclonal antibody production 
experiments and three mice per group were used in mouse strain difference experiment. 
Animal experiments were performed according to Institutional Guidelines for Animal 
Care and Handling, National University of Singapore.  
4.2.4.2 Immunization protocols 
4.2.4.2.1 DNA Delivery 
4.2.4.2.1.1 Intramuscular and electroporation 
The experiment was carried out according to the protocol described by Widera 
and co-workers. (Widera et al., 2000). In summary, mice were anaesthetized using 
CRC cocktail (Appendix A), 1 µl / g of body weight delivered with 1 ml Tuberculin 
Latex Free Syringe and BD 27G1/2 PrecisionGlide Needle, (Becton Dickinson, 
Franklin Lakes, NJ, USA). Each mouse received 50 µg (in 50 µl) of DNA delivered 
intramuscularly in the posterior thigh. The skin on the tibialis anterior muscle was 
shaved before injection. After the intramuscular injection, two-needle array electrodes 
(5mm) were inserted (to a depth of around 2 mm) at both ends of the injected site 
immediately for electroporation. The electroporation parameters were: Voltage: 82V, 
pulse length: 20 ms, Pulse: 4, Interval: 200 ms on a BTX ECM830 square wave 




the immunization schedule (Figure 7). Blood was extracted from orbital sinus to 















Figure 7: Immunization schedule for DNA immunization coupled with protein 
boost. Note: i.m.: intramuscular; i.p.: intraperitoneal; e: electroporation. 
4.2.4.2.1.2 Intrasplenic injection of DNA 
Intrasplenic injection was performed according to protocols described 
previously (Spitz et al., 1984; Velikovsky et al., 2000). Briefly, Balb/c mice were 
anaesthetized as described previously (4.2.4.2.1.1). The mice were placed on its right 
side.  The fur from the left side was shaved and the abdomen swabbed with 70% 
ethanol. A skin incision 1-1.5 cm long was made on the skin, followed by the muscular 
wall and abdominal wall until the spleen was exposed. The spleen was exteriorized by 
gently lifting its lower pole, and moved a little further with the aid of forceps. The 
needle was inserted deeply into the spleen and the DNA injected as the needle was 
pulled out, in order to spread the DNA   (50 µg in 50 µl) evenly through most of the 
spleen (Figure 8-9). 
i.m. DNA  
injection 
50µg/mouse+e 
IM Immunization  
Week                       0    1     2      3      4      5      6     7      8      9      10     11     12    14      15 
M1, M5 
  sacrificed 
Bleeding 
i.p. injection of 50µg of 
recombinant yBlot t 19 protein + 



















Figure 8: Immunization schedule of DNA immunization coupled with intrasplenic 
boost. Note: i.m. : intramuscular; i.s.: intrasplenic; e: electroporation. 
 
 
Figure 9: Immunization schedule with intrasplenic injection alone. 
4.2.4.2.2 Protein Delivery 
4.2.4.2.2.1 Intraperitoneal (i.p.) with alum 
200 µl of yeast-expressed Blo t 19 (250 µg / ml) containing 2 mg of alum 
(Whitehall Lab Pty Ltd., Punchbowl, Australia) was injected intraperitoneally into 
each mouse. This was performed as a booster shot to mice previously immunized with 
plasmid DNA expressing Blo t 19 (Figure 7).  
4.2.4.2.2.2 Subcutaneous (s.c.) with Complete/Incomplete Freund’s Adjuvant 
A mixture of 1:1 of protein solution to complete Freund’s adjuvant (CFA) 
(GibcoTM, Invitrogen, Carlbad, CA, USA) was set up. Each mouse was to receive 20 
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µg of protein in CFA. The mixture was homogenized on ice using Microson™ 
ultrasonic cell disrupter (Misonix Inc., Farmingdale, NY, USA).  Sonication was 
performed for 15 s, with 15 s intervals, until the mixture was homogenized. The same 
procedure was applied to protein + incomplete Freund’s adjuvant (IFA) (Gibco™, 
Invitrogen, Carlbad, CA, USA).   
The homogenized mixture of protein + CFA/IFA was transferred to a 1 ml 
Tuberculin syringe. Mice were anesthetized and each mouse received 100 µl of the 
mixture subcutaneously. 
Time Procedure performed 
Day 0 Blood collection, s.c. injection of 20 µg yBlo t 19 + CFA/mouse. 
Day 10 Blood collection, s.c. injection of 20 µg yBlo t 19 + IFA/mouse. 
Day 20 Blood collection, s.c. injection of 20 µg yBlo t 19 + IFA/mouse. 
Day 30 Blood collection.  
Table 10: Immunization schedule of protein immunization. Each mouse was 
immunized with 20µg of yeast expressed Blo t 19 (yBlo t 19)  coupled to either 
CFA/IFA subcutaneously.  
4.2.4.3 Fusion using ClonaCell™-HY 
Fusion was carried out according to the manufacturer’s instruction (StemCell 
Tech Inc., Vancouver, BC, Canada, Vancouver, BC, Canada). Briefly, 2 x 107 of log 
phase growing myeloma cells (P3X63Ag8.653) (American Type Cell Culture (ATCC), 
Manassas, VA, USA) were resuspended in 30 ml Medium A (MA) (StemCell Tech 
Inc., Vancouver, BC, Canada) (prewarmed to 37°C). 1 x 108 viable spleen cells were 
added to the P3X63Ag8.653 myeloma cells (ATCC, Manassas,VA, USA) and 
centrifuged at 400 x g for 5 minutes. The supernatant was discarded, pellet broken up 
by tapping on the side of the tube, and washed twice with 40ml of prewarmed Medium 




that, the supernatant was removed completely and the pellet was gently resuspended 
with 1 ml of PEG solution (prewarmed to 37°C) using 1ml pipet (Becton Dickinson 
and Company, Franklin Lakes, NJ, USA) over 1 minute, stir with pipet over 1-2 
minutes. 4 ml of MB was added over 4 minutes. 10 ml of MB was then added. After 
that, the mixture was incubated for 5 minutes in 37°C water bath. After that the 
mixture was washed twice with 40 ml of MA. Then the pellet was resuspended with 10 
ml Medium C (MC) (StemCell Tech Inc., Vancouver, BC, Canada, Vancouver, BC, 
Canada) and transferred to 250 ml tissue culture flask containing 40 ml MC for 
incubation overnight (16-24 hours), at 37°C. 
  The next day, the mixture of cells was centrifuged at 1200 rpm for 10 minutes. 
0.5 ml of the supernatant was used to resuspend the pellet while the remaining 
supernatant was discarded. After that, 10ml of MA was added. Meanwhile, a bottle of 
prewarmed Medium D (MD) (StemCell Tech Inc., Vancouver, BC, Canada) was 
stirred well with 10 ml pipet and 10 ml of cells added to it. The mixture was incubated 
for 30 minutes in 37°C, 5% CO2. After that, the mixture was plated out in ten 100 mm 
Petri dish. The plates were incubated in the CO2 incubator for 14 days.  
Two weeks later (10-14 days), colonies visible to the naked eye were picked 
and placed in 96-well plate (Nunc™, Nalge Nunc International Corp, Naperville, IL, 
USA) containing 200 µl of prewarmed Medium E (ME) (StemCell Tech Inc., 
Vancouver, BC, Canada) in each well. 
4.2.4.4 Screening of antibody secreting hybridoma clones 
4.2.4.4.1 ELISA for detection of poly/monoclonal antibody 
 
The ELISA protocol was similar to ELISA protocol described in 3.3.3 except 
that the allergens used were either GST-Blo t 19 (5 µg / ml), yBlo t 19 (5 µg / ml), 




hybridoma clones (50 µl / well). Rat anti-mouse immunoglobulins (Sigma-Aldrich, 
Saint Louis, MO, USA) (1 : 5000) was used as secondary antibody. Optical density 
reading was read at 15 minutes and 30 minutes at a wavelength of 405 nm. 
4.2.4.4.2 ELISA for isotyping of antibody 
The ELISA protocol was similar to ELISA protocol mentioned in 3.3.3 except 
that the coating antigen were yBlo t 19 (5 µg / ml) and Blo t extract (200 µg / ml), the 
primary antibody was hybridoma supernatant and the secondary antibody used was 
either rat anti-mouse IgG1, IgG2a, IgG2b, IgG3, IgM or IgE (Serotec, Oxford, UK) 
(working concentration: 250 ng / ml, rat anti-mouse IgA (Sigma-Aldrich, Saint Louis, 
MO, USA) (dilution factor: 1 : 10000) for the detection of the respective antibody 
isotype. 
4.2.4.5 Mantaining and expanding hybridoma clones 
Culture medium for hybridomas was changed when it turned from pink to 
yellow. 110 µl of the culture medium was collected from the wells for analysis using 
ELISA (4.2.4.4) and replaced with fresh ME. 
Positive clones were expanded into 24-well plate. Briefly, the clones were 
resuspended in their original 96-well (Nunc™, Nalge Nunc International Corp, 
Naperville, IL, USA) and transferred to 24-well plate (Nunc™, Nalge Nunc 
International Corp, Naperville, IL, USA) containing 1 ml of ME and cultured over 1 to 
2 days when additional 1 ml ME was added. Culture medium that turned yellow was 
collected for isotyping ELISA (4.2.4.4.2). Positive clones were further expanded into 
6-well plates (Becton Dickinson and Company, Franklin Lakes, NJ, USA) and some 
were frozen (4.2.4.7). From 6-well, the clones were subsequently adapted to HT 




Corning, NY, USA) and subsequently to T-75 flasks (Corning Inc., Corning, NY, USA) 
for ascites production (4.2.6.4). 
4.2.4.6 Subcloning by limiting dilution to purify monoclonal antibody 
producing clone 
The day before the cloning, 24-well plates were fed with fresh medium.  The 
next day, the cells were resuspended and 1 ml of the suspension was transferred a 
sterile 15 ml tube (Becton Dickinson and Company, Franklin Lakes, NJ, USA).  50 µl 
of this suspension was taken for cell viability count (viability should be >80%). For 
each hybridoma cell line, the dilutions to give 4 cells / ml, 2 cells / ml and 1 cell / ml in 
cloning medium were calculated. Serial dilutions were made accordingly to yield 4, 2, 
and 1 cell/ml. Then, the dilutions were plated out in 96-well plates (200 µl / well). The 
plates were incubated at 37oC, 5% CO2 for 5-7 days. With the help of microscope, the 
number of colonies formed was noted to determine cloning and plating efficiency. 
Refeeding was performed by adding 50 µl of fresh medium to wells with noticeable 
cells. 
4.2.4.7 Freezing of myeloma cell-line P3X63Ag8.653 and hybridoma clones 
Cell culture was resuspended and cell number counted using trypan blue 
exclusion method. The cell suspension was centrifuged at 400 x g for 8 minutes. 
Supernatant was discarded and the cell pellet was resuspended in fetal calf serum (FCS) 
(HyClone, Logan, Utah, USA). Then equal volume of FCS (HyClone, Logan, Utah, 
USA) containing 20% DMSO (Sigma-Aldrich, Saint Louis, MO, USA) was added to 
yield the final cell concentration of 5 x 106 to 1 x 107 cell / ml. The cell mixture was 




Naperville, IL, USA) and freeze at -20°C for half an hour, followed by -86°C 
overnight and finally transferred to liquid nitrogen for long term storage. 
4.2.4.8 Thawing of myeloma cell-line P3X63Ag8.653  
One vial of cells from -86°C or liquid nitrogen was thawed in 37°C water bath 
for a few minutes. Then the cell suspension was removed and added dropwise into a  
20 ml room temperature MA. The suspension was then centrifuged at 400 x g for 8 
minutes. The supernatant was discarded and the cell pellet resuspended in 30 ml of 
Medium A and transferred to a T-75 flask for incubation overnight at 37°C, 5% CO2 
incubator. 
The second day, the suspension was resuspended and the flask was left to stand 
vertically in the incubator for 30-60 minutes. After that, around 20 ml of medium was 
removed and replaced with fresh medium. The cell culture was then left to incubate for 
a 2-3 days. The cell culture was split accordingly to yield the required number of cells 
for fusion. 
4.2.4.9 Thawing of hybridoma clones 
One vial of cells was thawed in 37°C water bath for a few minutes.  The vial 
was removed from the water bath when the ice has just melted and the cell suspension 
was diluted by the dropwise addition of the cell suspension to an equal volume HT 
medium (Appendix B). The suspension was left to stand for 5 minutes before an equal 
volume of HT medium (Appendix B) was added. The suspension was left for a further 
5 minutes and finally centrifuged at 400 x g for 5 minutes. After the supernatant had 
been discarded, the cell pellet was resuspended in 5 ml of HT medium and cultured in 




4.2.5 Mouse strain difference study 
Different strains of mice were selected: Balb/c, Balb/cJ, AKR, CBA, C57/B6. 
Three mice from each strain were used for the experiment. Each mouse was treated 
with i.p injection of 50 µg of yBlo t 19 and alum three times within 4 weeks (one dose 
biweekly). Blood samples were collected for analysis on day 0, day 10 and day 17. 
Besides that, 2 groups of mice (5 Balb/c and 5 Balb/cJ) were used to study the 
responses to i.m. injection of plasmid DNA (pC1-Derp5L-Blo t 19) with 
electroporation. The mice were treated with 50 µg / mouse of plasmid plus 
electroporation biweekly until each mouse received 3 doses of plasmid injections. 
Blood samples were collected for analysis weekly. 
4.2.6 Identification and Purification  
4.2.6.1 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein samples were analyzed by SDS-PAGE modified from the method 
previously described (Laemmli, 1970). In brief, protein samples were mixed 1:1 with 
2X SDS-PAGE sample buffer (Appendix A) and were boiled for 10 minutes. Samples 
were separated on a 15 % Tris-Glycine (or other gel percentage as stated) denaturing 
gel (Appendix A) using the Mini PROTEAN electrophoresis system (BioRad, 
Hercules, CA, USA). Gel was run at 120 Volts for 90 minutes. Broad Range Marker 
(BioRad, Hercules, CA, USA) was used as standard. All SDS-PAGE gels were stained 




4.2.6.2 Western Blot 
Gel was run according to instructions from gel/apparatus manufacturer. 
Typically, gels were run at 110V constant voltage. Electrophoresis was stopped when 
the dye front was about 1 cm from the bottom of the gel. 
Transfer of protein from gel to nitrocellulose membrane was performed 
according to manufacturer's instructions. After transfer, the membrane was blocked in 
blocking solution (1X PBS, 0.05% Tween 20, 5% Skim milk on a rocker platform for 
60 minutes at room temperature. After that, the membrane was incubated in primary 
antibody (hybridoma supernatant / ascites / purified monoclonal antibody / biotinylated 
monoclonal antibody) diluted in blocking solution (1 : 1000 / 1 : 4000) on a rocker 
plate overnight at 2-8 oC. 
The membrane was then washed 6 times for a minimum of 5 minutes each in 
wash solution (1X PBS, 0.05% Tween 20). After that, the membrane was incubated in 
secondary antibody conjugate (anti mouse total immunoglobulin biotin conjugated   
(1 : 5000) / anti mouse isotype biotin conjugated (1 : 2000) diluted in fresh wash 
solution) for 60 minutes at RT on a rocker plate. The wash process was then repeated, 
followed by the addition of ExtrAvidin® (alkaline-phosphatase and peroxidase-
conjugated) (Sigma-Aldrich, Saint Louis, MO, USA), 1 : 5000 dilution in wash 
solution and incubation for 1 hour at room temperature on rocker. 
After an hour, the membrane was washed as previously described. Substrate 
(SuperSignal® West Pico Chemiluminescent Substrate, Pierce, Rockford, IL, USA) 
was then added, followed by incubation time of 5 minutes on rocker. 
For development, the membrane was wrapped in plastic that fits in the cassette 




Company, Rochester, NY, USA) was exposed to the membrane in dark room. 
Exposure time was reduced or increased accordingly to reduce unspecific signal. 
For colorimetric reaction, the membrane was removed from the plastic and 
rinsed with Milli-Q water followed by 2X with wash solution for 5 minutes each. It 
was then incubated for 20-30 minutes with 20 ml (big Petri dish) 1x AP buffer 
containing 200 µl each of AP color reagent A and B (Bio-Rad Laboratories, Hercules, 
CA, USA). The membrane was washed with Milli-Q water and dried for record when 
satisfactory signal intensity was observed. 
4.2.6.3 Gel staining 
All the steps were performed with constant shaking at room temperature 
(~25ºC) unless otherwise specified. 
4.2.6.3.1 Coomasive blue staining 
SDS-PAGE gel was rinsed briefly in water. Then the gel was immersed in 
around 100 ml of Coomasive blue stain for ½ to 1 hour. After that, the gel was 
destained using around 100 ml of destaining solution for ½ to 1 hour. The destaining 
solution was then replaced and destained for a further of 1 to 2 hours, after which, the 
destaining solution was replaced with Milli-Q water. The gel was soaked in around 
100 ml of Milli-Q water with two to three changes, 30 minutes between each change, 
before it was left overnight in Milli-Q water. The gel was framed and dried overnight 
the next day. 
4.2.6.3.2 Silver staining 
SDS-PAGE gel was fixed in 200ml of fixing solution (50% (v/v) methanol, 5% 
(v/v) acetic acid in water) for 30 minutes. Then, the gel was washed with 200ml of 




water. After that, the gel was sensitized in 200ml of sensitizing solution (0.02% (w/v) 
sodium thiosulfate (Merck, Darmstadt, Germany) for 2 minutes. Then, it was washed 
with 200 ml of Milli-Q water twice, 1 minute each. After removing the water, the gel 
container was wrapped in aluminum foil to protect from light. 50 ml of chilled 0.1% 
silver nitrate (AgNO3) was then added and incubation was carried out in 4ºC for 40 
minutes with constant shaking. Thereafter, the gel was washed twice with 200 ml 
Milli-Q water, 1 minute each. 
Development was performed by replacing the Milli-Q water with 100 ml of 2% 
sodium bicarbonate (NaHCO3) (Sigma-Aldrich, Saint Louis, MO, USA) containing 
0.04% (v/v) formalin (37% formaldehyde in water) (Sigma-Aldrich, Saint Louis, MO, 
USA) and constantly shaken for 15 s. Then, the developing solution was replaced with 
100 ml of fresh developing solution and incubated until bands with the required 
contrast appeared (5-10 minutes). Then, the developing solution was discarded and 
replaced with 200 ml of stop solution (3.65 g / 250 ml Na2EDTA.2H2O) and incubated 
for 10 minutes. The gel was then washed thrice with 200 ml of Milli-Q water, 10 
minutes each. After this, the gel could either be framed. 
4.2.6.4 Ascites production 
All animal handling were performed in compliance with local regulations. Mice 
(Balb/c) were primed by intraperitoneal (i.p.) injection of 0.5 ml of Pristane (Sigma-
Aldrich, Saint Louis, MO, USA) 1-2 weeks before cell injection. Hybridoma cells 
grown in T-75 culture flasks (Corning Inc., Corning, NY, USA) were harvested in log 
phase and the viability by trypan blue exclusion. The cells were centrifuge at 1000 x g 
for 10 minutes at 20˚C. The pellet was washed twice in PBS (20 ml each time) and 




5 x 106 cells in 1 ml PBS was injected i.p. into each mouse via the lower left 
quadrant from the midline. After around 10 days, when liquid tumor formation was 
noticeable (stomach of mice started bulging), ascitic fluid was extracted from the 
peritoneal cavity with an 18-G needle over a 15 ml tube. The ascites was left at room 
temperature for around 1 hour at 37ºC. Then, the fluid was kept overnight at 4ºC. The 
next day, the ascites was centrifuged at 3000 x g, 10 minutes, at 4˚C to remove cells 
and debris, and the clear supernatant was collected (discarding oil). The clear 
supernatant was aliquoted in 1 ml each in 1.5 ml microcentrifuge tube and stored at -
80˚C. Mice were tapped 2-3 times (every 2-3 days) before being sacrificed. 
4.2.6.5 Biotinylation of monoclonal antibody 
Purified monoclonal antibodies (AF6 and I3D3) were diluted with coupling 
buffer to a concentration of 2 mg / ml (total volume 500 µl). An aliquot of 50 µl of 
biotinylation reagent (Biotinamidocaproate N-hydroxysuccinimide ester (Sigma-
Aldrich, Saint Louis, MO, USA), 1 mg / ml in DMSO (Sigma-Aldrich, Saint Louis, 
MO, USA) was added to each antibody preparation. The biotin:antibody ratio used was 
approximately 10:1. The mixture was incubated overnight at 4°C with constant gentle 
shaking. To stop the reaction, 10 µl of 16.7 M ethanolamine (Sigma-Aldrich, Saint 
Louis, MO, USA) was added and the mixture was gently mixed at room temperature 
(22-25ºC) for 2 hours. The mixture was then dialyzed extensively in coupling buffer at 
4°C to remove excess biotin. The biotin-conjugated antibodies were stored in aliquots 
in -20ºC until use. 
4.2.6.6 Monoclonal antibody specificity determination 
The specificity of the antibody was determined using direct ELISA and 





4.2.6.6.1 Direct ELISA 
ELISA plate was coated with either 500 ng of yBlo t 19, 20 µg Blo t extract or 
coating buffer alone. Primary antibody used was hybridoma supernatant from AF6 
hybridoma. The supernatant was used without any dilution. The secondary detection 
antibody was rat anti-mouse IgG1 biotin conjugated (1 : 2000). Other than the above 
modification, the ELISA protocol was as previously described (3.3.3). 
4.2.6.6.2 Absorption study using ELISA  
The ELISA protocol was as previously described (3.3.3) except for the 
following modifications. Briefly, AF6-biotin (1 : 4000) was dispensed 50 µl / well into 
plates coated with 500 ng / well of GST-Blo t 19, yBlo t 19, GST or coating buffer 
alone (blocked and washed as previously described (3.3.3)) and incubated overnight at 
4ºC. The next day the liquid from each well was transferred to another plate coated 
with the either GST-Blo t 19 or yBlo t 19 and incubated overnight. The plate was then 
washed and ExtrAvidin® alkaline phosphatase conjugate (Sigma-Aldrich, Saint Louis, 
MO, USA) (1 : 2000) was added into each well (50 µl / well) and processed 
accordingly as previously described (3.3.3). 
4.2.6.6.3 Absorption study using western blot 
1.3 µg of purified AF6 was incubated overnight with either 20 µg or 5 µg of 
GST-Blo t 19 or 1X PBS overnight at 4ºC on a rotater with constant rotation. These 





4.2.6.7 Purification of monoclonal antibody from ascites 
4.2.6.7.1 Packing of Protein G column 
The Protein G column was packed according to the manufacturer’s instruction. 
Briefly, frit was soaked in 20% ethanol. It was pressed to remove trapped air. The 
barrel of the column (Pierce, Rockford, IL, USA) was half filled with wash/binding 
buffer. The soaked frit was then pushed into the barrel until it rested firmly on the 
bottom. The cap of the column was then removed to let the flow start. The column was 
washed with 5 column volumes of 1X wash/binding buffer. A suspension of 1:1 
Protein G agarose beads (Kirkegaard & Perry Laboratory, Gaithersburg, Maryland, 
USA) in 1X wash/binding buffer was prepared. The slurry was then poured into the 
column. The column was allowed to flow so that it was packed by gravitational pull. 
The packed affinity resin was equilibrated with 10 column volumes (CV) of 
wash/binding buffer. 
4.2.6.7.2 Purification of mAb using Protein G column 
Ascites fluid was diluted in wash/binding buffer (1:1). A sample was taken for 
SDS-PAGE. Gently, the 1:1 suspension was applied to the column. The flowthrough 
was collected in a clean tube. A sample was taken for SDS-PAGE. The column was 
then washed with 10 CV of wash/binding buffer or until the Abs280nm approached 0. 
Before elutiing, enough tubes (usually 6-8 tubes) were set aside, each containing     
240 µl of 5X wash/binding buffer. To elute the antibody, the elution buffer was added 
1ml at a time. Each 1 ml was collected in different tubes. Samples were taken from 
each tube (usually 10 µl) for SDS-PAGE gel analysis. Once the sample has been eluted, 




of 1X wash/binding buffer. After the equilibration of the column, the wash/binding 
buffer in the column was replaced with storage buffer and the column was kept in 4˚C. 
4.2.6.7.3 Preparation of dialysis tubing and dialysis 
The dialysis tubing was prepared according to the protocol described 
previously (Sambrook et al., 1989). Briefly, 10-20 cm long tubing was cut. The tubing 
was boiled for 10 minutes in large volume of 2% (w/v) sodium bicarbonate and 1 mM 
EDTA (pH 8.0). The tubing was then rinsed thoroughly in distilled water and boiled 
again in 1 mM EDTA (pH 8.0) for 10 minutes. The tubing was allowed to cool, then 
stored at 4˚C. Before use, the tubing was washed inside and out with distilled water.  
Typically, protein solution was dialyzed in at least 500 times sample volume in 
suitable buffer overnight at 4ºC with 3 changes of buffer. 
4.2.6.8 Coupling of monoclonal antibody to Sepharose beads 
The Sepharose beads were treated according to the manufacturer’s instructions. 
Briefly, 0.7 g (good for a 2 ml column) of CNBr-activated Sepharose 4B (Amersham 
Biosciences, Buckinghamshire, UK) was resuspended in 5 ml of 1.0mM HCl and 
allowed to swell by gentle shaking (3-5 minutes). Then the beads were washed with a 
total of 200 ml of 1 mM HCl using a column. After that, the beads were resuspended 
with 10 ml coupling buffer (0.1M NaHCO3, 0.5M NaCl, pH8.3). The suspension was 
centrifuged at 2000 rpm (Jouan BR4i Centrifuge) for 5 minutes at 4˚C. The 
supernatant was discarded by aspirating. Then the beads were again resuspended in 5 
ml coupling buffer and transferred to a 15 ml centrifuge tube. Around 1 mg of purified 
antibody was added to the suspension. Total volume of the suspension was adjusted 




overnight at 4˚C with gentle shaking on Bio Dancer (New Brunswick Scientific, 
Edison, NJ, USA).  
The next day, the suspension was centrifuged at 2000 rpm (Jouan Centrifuge) 
for 5 minutes at 4˚C. The supernatant was discarded and the beads resuspended with   
4 ml blocking buffer (1 M ethanolamine, pH 8.0). The suspension was then incubated 
for 2 hours at room temperature (~25°C) with gentle shaking, after which the 
suspension was centrifuged again at 2000 rpm (Jouan Centrifuge) for 5 minutes at 4˚C 
to remove supernatant. A sample of the supernatant from each stage was collected to 
be analyzed using SDS-PAGE to check the coupling efficiency. 
Finally, the beads were resuspended with 10 ml 1X TBS and pack in column or 
store at 4˚C for future use. 
4.2.6.9 Purification of native protein / yBlo t 19 
Previously packed column was washed with 1X TBS (pH 7.5) until OD280nm = 
0. 10 ml of Blo t mite crude extract (around 200-400 mg of protein) was then loaded to 
the column. Then, the column was washed with 10 CV of 1X TBS until OD280nm 
approached 0. Elution with acidic condition was performed by adding 8 x 0.8 ml of 
acidic elution buffer (5mM Glycine (Sigma-Aldrich, Saint Louis, MO, USA), pH 2.7). 
Each 0.8 ml fraction was collected in 1.5 ml centrifuge tube containing 0.2 ml of 5X 
TBS pH 7.5 (for neutralizing the acidic condition).  
After elution with acidic condition, the column was washed with 10 CV of 1X 
TBS. Wash until OD280nm approached 0. Elution with basic condition was performed 
by adding 8 x 0.8 ml of basic elution buffer (5mM Glycine (Sigma-Aldrich, Saint 
Louis, MO, USA), pH 11) to the column. Each fraction was collected in 1.5 ml 
centrifuge tube containing 0.2 ml 5X TBS. Finally the column was washed with 20 CV 




replaced with storage buffer (0.01 M NaH2PO4, 0.15 M NaCl, 2.7 mM KCl, pH 7.4, 
20% ethanol), capped and kept in 4˚C. 
300 µl from each fraction was collected for analysis. These samples were 
lyophilized and dissolved in 20 µl of sample buffer. Then, they were boiled and 
analyzed with SDS-PAGE (15% Tris-Glycine gel). After that, the protein was detected 
using silver staining. 





4.3.1 Blo t 19 sequence 
Blo t 19 is a cysteine-rich protein with a deduced mature protein sequence of 
66 residues (Figure 10).  It has a theoretical molecular weight of 6792.67 daltons and 
isoelectric point (pI) value of 8.77 (calculated using Compute pI/Mw tool from Expaxy 
(http://tw.expasy.org/tools/pi_tool.html)).  
 
                                                                                                                                                          35                                  
                                                               gg   cca   gag   cac   ccc   gct   caa  gct   ctc   gac  ttt   acc  
                                                                                         H      P      A     Q    A    L     D     F     T      
                                                                                                                                                           95 
agc tgt   gcc  cgg   atg   aac   gat    gga  gct   ctg    gga   gcc   aag   gta   gct  caa   gct   gcc  tgc  atc 
S    C    A      R      M     N     D     G     A     L      G      A      K      V     A     Q    A     A      C     I        
                                                                                                                                                          155 
tcg  agt  tgc   aag   ttt    caa    aac   tgt    ggc   acg   gga   cac   tgt    gag   agg  cga  ggt  gga  cgt   cca 
S     S    C      K     F     Q       N     C     G      T      G      H       C     E      R     R     G    G     R      P  
                                                                                                                                                          215 
acc  tgt  gtc    tgt    tct   cgc   tgt   ggc   aac   ggt    ggc   ggt    gaa   tgg   ccc  aat   ctg  ccc   tcc   agg  
T     C    V     C      S     R      C      G      N     G       G     G      E     W      P      N     L    P      S    R     
                                                                                                                                                            275 
ggt  taa   tta   ttt    tgt    cat     ttg   gtc    tgt     gaa   agt    gtg    aca   cac   tat    tta   tat   atg   ctt   tca  
G     -                                                                                                                                                   335 
ata  gga  ata   acc   ttc    aat     ttt    ggt   cac    act    ttc     cca    tca   att     ttt    gac  aat   ttc   aaa  att  
                                                                                                                                                            395 
aat  taa  ggt    ttt    att     tta     aag  ttc    atc    aat    ttt      ttg     tgg   ctt    tat     ttt    ttt   aaa   att  atc  
                                                                                                                                                            455 
cga gat  gtt    tga   cag   aga    caa   ttg   att     aat    taa    aat     aat    ttt    tta     aat   tta   aaa   att   gtt 
                                                                                                                                                            507 
tta  taa   ata   aaa   att     ttt     tat    ttt    tgg    aaa   aaa    aaa    aaa    aaa  aaa   aat   tcg   t 
 
Figure 10: Nucleotide sequence and the deduced amino acid sequence of Blo t 19. 
Number indicates the nucleotide position. The nucleotide sequence of the clone is 
507bp in length.  This includes a linker sequence ggccagag (blue), a 286bp 3’ 
untranslated region with a poly-A tail, and a 218bp coding region for the 
recombination protein with a stop codon (TAA) at nucleotide residues 219-221. 
The inferred amino acid sequence from nucleotides 9 –218 indicated that this 






ASABF           GCAGTCGACTTTTCATCATGCGCACGTATG---GATGTACCTGGATTGAGCAAAGTGGCG 
Blo t 19        GCTCTCGACTTTACCAGCTGTGCCCGGATGAACGATGGAGCTCTGGGAGCCAAGGTAGCT 
 
ASABF           CAAGGATTATGCATATCTTCTTGCAAATTCCAGAATTGTGGTACCGGTCACTGTGAGAAG 
Blo t 19        CAAGCTGCCTGCATCTCGAGTTGCAAGTTTCAAAACTGTGGCACGGGACACTGTGAGAGG 
 
ASABF           CGTGGTGGTCGACCGACGTGTGTTTGCGATCGATGTGGACGAGGGGGCGGTGAATGGCCA 
Blo t 19        CGAGGTGGACGTCCAACCTGTGTCTGTTCTCGCTGTGGCAACGGTGGCGGTGAATGGCCC 
 
ASABF           AGCGTACCTATGCCAAAAGGGCGAAGTTCACGTGGACGAAGGCATTCTTA 
Blo t 19        A----ATCTGCCCTCCAGGGGTTAA------------------------- 
                        
Figure 11: Alignment of Blo t 19 nucleotide sequences with ASABF nucleotide 
sequences encoding for the mature ASABF protein using ClustalW 




ASABF           AVDFSSCARMDVPGL-SKVAQGLCISSCKFQNCGTGHCEKRG 
Blo t 19        ALDFTSCARMNDGALGAKVAQAACISSCKFQNCGTGHCERRG 
 
ASABF           GRPTCVCDRCGRGGGEWPSVPMPKGRSSRGRRHS 
Blo t 19        GRPTCVCSRCGNGGGEWPNLPSRG---------- 
    
Figure 12: Alignment of  Blo t 19 deduced amino acid sequence with ASABF 
mature protein sequence using Clustal W (http://clustalw.genome.ad.jp/). 
Matched sequences were highlighted (cyan). Matched cysteine residues were 
specially highlighted in yellow. 
 
BLAST results revealed that Blo t 19 has high amino acid identity (70-76%) 
with Ascaris suum antibacterial factor (ASABF) (Accession number: BAA11943, Kato 
& Komatsu, 1996) and ASABF-family proteins, namely ASABF-beta (BAC00497), -
gamma (BAC00498), -delta (BAC00499), and –zeta (BAC57992). 
Blo t 19 aligned well with both the nucleotide and amino acid sequences of 




 To deduced the possible structure of Blo t 19 based on information on ASABF, 
the cysteine array of Blo t 19 was compared with other Cysteine-Stabilized αβ (CSαβ) 
(Cornet et al., 1995)-type peptides as previously described (Zhang & Kato, 2003). 
 
ASABF         ---MKTAIIVVLLVIFASTNAAVDFSSCARMDVPGL-SKVAQGLCISSCKFQN--CGTGHCE 
Blo t 19      ---------------------ALDFTSCARMNDGALGAKVAQAACISSCKFQN--CGTGHCE 
MGD-1         ------------------------GFGCPNNYQ-----------CHRHCKSIPGRCG-GYCG 
Myticin A     ---MKATILLAVLVAVFVAGTEAHSHACTSYW------------CGKFCGTAS--CTHYLCR 
                                            
 
ASABF         KRG-GRPTCVCDRCGRGGGEWPSVPMPKGRSSRGRRHS-------------- 
Blo t 19      RRG-GRPTCVCSRCGNGGGEWPNLPSRG------------------------ 
MGD-1         GW—-HRLRCTCYRC-------------------------------------- 
Myticin A     VLH-PGKMCACVHCSRVNNPFRVNQVAKSINDLDYTPIMKSMENLDNGMDML 
 
Figure 13: Comparison of cysteine array (highlighted) in Blo t 19 with other 
CSαβ-type peptides. 
 
Cysteine array comparison showed that Blo t 19 shared conserved cysteine 
arrangements with other CSαβ-type peptides (Figure 13). This suggested Blo t 19 and 
ASABF having similar motif: CSαβ (Cornet et al., 1995). This motif is made of three 
distinct domains: an amino-terminal loop, a single α-helix and a two-stranded 
antiparellel β-sheet; the three of them were stabilized by disulfide bridges (Cornet et 






4.3.2 Human IgE reactivity to Blo t 19 
The importance of Blo t 19 human IgE reactivity was studied using plaque 



















Figure 14: The plaque immunoassay showing the IgE reactivity of 20 sera tested 
with the recombinant protein Blo t 19. Panel number 2, 3, 4, 5, 6, 7, 8, 9, 11, 15, 16 
and 17 are positive. Panel number 1, 14, 18 and 20 are slightly positive whereas 
panel number 10, 12, 13 and 19 are negative.  
 Plaque immunoassay showed that Blo t 19 was allergenic, binding IgE from 
16/20 of the Blo t extract sensitized individuals (Figure 14). 
1 2 4 3 5 6 7 8 9 






Reaction of rhinitis subjects to GST-Blo t 19 (after 

















Figure 15: Allergenicity of GST-Blo t 19 among rhinitis subjects who were 
positive to Blo t extract. Cut off value was determined using mean plus two 
standard deviations of 10 healthy non-allergic subjects. 
  The Blo t 19 gene was expressed as a GST-fusion recombinant protein (GST-
Blo t 19) by another colleague in the laboratory. Nonetheless, when GST-Blo t 19 was 
tested for its allergenicity using another panel of subjects, only 2/12 individuals reacted 





4.3.3 Southern blot analysis 
 
    DIG- 
    Labeled    ~ 20µg of      Der f DNA  




Figure 16: Detection of an around 4-.4.3 kb (white arrow) fragment in Blo t 
genomic DNA. Der f genomic DNA as negative control. All genomic DNA was 
digested  with HindIII (Promega, Madison, USA). 
Southern blot analysis revealed consistently a band of around 4-4.3 kb in the 












4.3.4 Monoclonal antibody generation 
4.3.4.1 Cloning of Blo t 19 gene into pC1Derp5L expression vector 




           
Figure 17: A: PCR u
I gene fragment from





























                              
sing high fidelity polymerase to generate BspE1-Blo t 19-Not 
 pGEX-Blo t 19 clone; B: Purified PCR product. 
showed the PCR product produced using pGEX-Blo t 19 as 
9 (Table 7) and Bt19-Not I (Table 7) as forward and reverse 
 showed the analysis of gel-purified PCR product (purified as 
















































                                                                                         
Figure 18: A: Restriction enzyme analysis of Blo t 19-TOPO clone; B: PCR 
product of Blo t 19 from Blo t 19-TOPO clone using M13 forward and reverse 
primers; C: PCR product using gene specific primers (BspE1-Blo t 19 and Blo t 
19-Not I). 
 Figure 18A showed the result of restriction enzyme (RE) analysis of Blo t 19-
TOPO clone. RE digestion released a fragment of ~200bp (identical to the one shown 
in Figure 17A-B) indicating positive result. Further analysis using PCR (Figure 18B-C) 
further proved that the clone was positive. Lastly, the clone was confirmed with 






    TOPO-Blo t 19  TOPO-Blo t 19 
 
Figure 19: Preparation of BspE1-Bt19-Not I from TOPO-Bt19 
 Figure 19 showed the large-scale preparation of BspE1-Bt19-Not I gene 
fragment for cloning into pC1Dp5L vector (Figure 19). The Blo t 19 insert was gel-
purified (4.2.2.5) and used for ligation. 
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Figure 20: Preparation of BspE1-Not I linearized pC1Dp5L vector from 
pC1Dp5L-Blo t 3 
 
 Figure 20 showed the large-scale preparation of the pC1Dp5L vector (Figure 
20). The BspE1-Not I linearized vector was gel-purified (4.2.2.5) and used for ligation. 












































9                                             
 A: Gel purified linearized vector and insert; B: pC1Dp5L-Bt19 
: Analysis of pC1Dp5L-Bt19 after treatment with BspE1 and Not I 
enzymes. 
re 21A showed the result of gel purification of both the vector and insert 
 Figure 21B-C showed the analysis of the pC1Dp5L-Bt19 clone using gel 







































pC1Dp5L-Bt19    CTCCNNTCAATTCAGCTCTTAGGCTAGAGTCTTAATACGACTCACTATAGGCTAGCCTCT 
Bt19FL          ------------------------------------------------------------ 
                                                                             
 
pC1Dp5L-Bt19    CGCCACCATGAAATTCATCATTGCTTTCTTTGTTGCCACTTTGGCAGTTATGACTGTTTC 
Bt19FL          ------------------------------------------------------------ 
                                                                             
 
pC1Dp5L-Bt19    CGGAGCTCTCGACTTTACCAGCTGTGCCCGGATGAACGATGGAGCTCTGGGAGCCAAGGT 
Bt19FL          ----GCTCTCGACTTTACCAGCTGTGCCCGGATGAACGATGGAGCTCTGGGAGCCAAGGT 
                     
pC1Dp5L-Bt19    AGCTCAAGCTGCCTGCATCTCGAGTTGCAAGTTTCAAAACTGTGGCACGGGACACTGTGA 
Bt19FL          AGCTCAAGCTGCCTGCATCTCGAGTTGCAAGTTTCAAAACTGTGGCACGGGACACTGTGA 
                 
pC1Dp5L-Bt19    GAGGCGAGGTGGACGTCCAACCTGTGTCTGTTCTCGCTGTGGCAACGGTGGCGGTGAATG 
Bt19FL          GAGGCGAGGTGGACGTCCAACCTGTGTCTGTTCTCGCTGTGGCAACGGTGGCGGTGAATG 
                 
pC1Dp5L-Bt19    GCCCAATCTGCCCTCCAGGGGTTAAGCGCATTCTTATAAGGGCGAATTCTGCAGATATCC 
Bt19FL          GCCCAATCTGCCCTCCAGGGGTTAA----------------------------------- 
 
pC1Dp5L-Bt19    ATCACACTGGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAAC 
Bt19FL          ------------------------------------------------------------ 
Figure 22: Alignment of one of the pC1Dp5L-Bt19 clones with Blo t 19 forward 
sequence. Matched sequences were highlighted (cyan). 
  
Figure 22 showed the analysis of the sequencing result of pC1Dp5L-Bt19 
(Figure 22). The result confirmed the clone was carrying Blo t 19 gene (Figure 22). 




































Figure 23: Mice antibody responses to GST-Blo t 19 after DNA immunization 
(blue arrow) and after protein boost with yeast-expressed Blo t 19 (black arrow). 
Mice did not react to Glutathione S-transferase (GST). 
  
Figure 23 showed the immune responses of mice immunized with plasmid 
DNA encoding for Blo t 19 through i.m. and with electroporation. Antibody titre was 
very low after 3 doses of DNA immunization and electroporation (Figure 23). The 
mice had to be boosted with Blo t 19 expressed in Pichia pastoris (yBlo t 19) four 
times before fusion could be performed. The use of GST-Blo t 19 as screening reagent 
instead of yBlo t 19 was to show that both forms of protein could be used 
interchangeably as the mice that were immunized with yBlo t 19 could also react to 
GST-Blo t 19. The GST-form of Blo t 19 was preferred as it was purified whereas 
yBlo t 19 was from culture supernatant. 






























































































































Figure 24: Isotyping of mice sera prior splenectomy. Mice sera were diluted 500 
times. Note: Tig: Total antigen-specific immunoglobulins; yBt19: yBlo t 19 
 
Isotyping of the sera prior fusion revealed a high IgG1 against yBlo t 19 and 
low IgG2a. The titer of IgM against yBlo t 19 was much lower compared to IgG1 
(Figure 24) at the point the fusion was carried out. 
Both intrasplenic delivery of DNA and s.c. delivery of Blo t 19 with CFA/IFA 
did not induce any detectable antigen specific antibody responses in the mice tested. 





4.3.4.3 Characterization of the monoclonal antibody produced 
4.3.4.3.1 Isotype of monoclonal antibody produced 
Isotypes Numbers Remarks 
IgG1 1 AF6, good titre 
Total 1  
Table 11: Blo t 19 specific monoclonal antibody generated from mice immunized 
by i.m. Blo t 19 DNA + electroporation + i.p. recombinant protein boost. A total of 
9 hybridomas were obtained and screened. 
 
Isotypes Numbers Remarks 
IgG2a 1 Very low titre (I3D3) 
IgM 10  
IgA 2 Very low titre 
Total 13  
Table 12: Monoclonal antibody generated from mice immunized by i.m. Blo t 19 
DNA + electroporation + i.s. injection of Blo t 19 DNA. A total of 301 hybridomas 
were obtained and screened. 
 
Isotypes Numbers Remarks 
IgM 6 Reacted against Blo t 
extract only 
Total 6  
Table 13:  Monoclonal antibody generated from mice immunized by i.s. injection 





4.3.4.3.2 Specificity of Bt19  monoclonal antibody (AF6) 
4.3.4.3.2.1 ELISA 
 


















Figure 25: Screening of AF6 hybridoma supernatants using yBlo t 19 and Blo t 
extracts. Negative control was cell culture medium alone without antibody. The 
antibody was detected using rat anti-mouse IgG1 biotin conjugated (1:2000). 
 
 Figure 25 showed the screening results of AF6 hybridoma supernatants using 
yBlo t 19 and Blo t extracts (Figure 25). Negative control was cell culture medium 
alone without antibody. The antibody was detected using rat anti-mouse IgG1 biotin 
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Figure 26: Activity of different dilutions 
recombinant Blo t 19 and Blo t extract. N
was wells without antibody. 
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Figure 27: Specificity of AF6 mAb to GST-Blo t 19 through absorption study. 
Antigens listed on x-axis were used to absorb AF6-biotin and tested against 
antigens: yBlo t 19 (blue) and GST-Blo t 19 (red). 
  
As shown in Figure 27, AF6 was very specific against GST-Blo t 19. It did not 
react to GST at all. Its binding to yBlo t 19 was weak compared to GST-Blo t 19 as 





4.3.4.3.2.2 Western Blot 
 








Figure 28: A: Western blot result of antibody AF6 without prior
20 µg of GST-Blo t 19; B: with prior incubation of 20 µg of GST
Glutathione S-transferase. Each lane was loaded with 0.5 µg of pr
  
Figure 28 further showed the specificity of AF6 to GST-Blo
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Figure 29: Detection of Blo t 19 in mite extract yBlo t 19 (white arrows) using 
western blot by AF6 (1:1000).  Negative control was another unrelated yeast 
expressed Blo t allergen. 
 
 AF6 could be used to detect Blo t 19 in Blo t mite extract as well as yBlo t 19 

























4.3.4.4 Purification of monoclonal antibody from ascites fluid 
                    
                          BRM  Bef     E1        E2        E3     E4     E5       E6        E7      E8        E9      E10      Af 
 
 
Figure 30: Purification of AF6 from ascites. BRM: Broad Range Marker (Bio-
Rad) (the relevant sizes marked); E1-E10: samples from eluted fractions. Bef: 
ascites before purification; Af: ascites after going through the column. 
 Purified AF6 antibodies were pooled together (E2 to E9) (Figure 30) for 















4.3.4.5 Purification of native Blo t 19 
                             
                         BRM    Bef          A1        A2        A3        A4       A5       A6      A7  A8 
 
Figure 31: Purification of Pichia pastoris expressed yBlo t19 using AF6 mAb 
immunoaffinity column --- a proof of concept. BRM: Broad range marker (Bio-
Rad); A1-A8: samples from eluted fractions using acidic elution buffer. Bef: 
sample before purification. 
 AF6 immunoaffinity column was proven to be able to purify Blo t 19 expressed 
in Pichia pastoris (Figure 31). 
 However, isolation of native Blo t 19 from the crude mite extract was not 
successful when the same AF6 monoclonal antibody immunoaffinity column was used 

























Figure 32: Antibody responses (total antigen-specific immunoglobulins) between 
mouse strains in response to i.p. injection of alum-coupled yBlo t 19. Each data 


















Figure 33:  Antibody responses of DNA immunized Balb/c mice to GST-Blo t 19. 






Mouse strain difference response to i.p. 




























































Figure 34: Antibody responses of DNA immunized Balb/cJ to GST-Blo t 19. Mice 
sera were diluted 250 times. Mice sera did not react to GST. 
 
 Mice from different strains reacted differently to yeast recombinant Blo t 19 
delivered via i.p. with alum (Figure 32). C57/B6, CBA and AKR responded well to 
this immunization protocol and gave high antibody responses. On the other hand, 
Balb/c and Balb/cJ which were usually used for monoclonal antibody generation 
experiments (Westerwoudt et al., 1984; Hong et al., 1989; Kilpatrick et al., 1997; 
Moonsom et al., 2001; Kasinrerk et al., 2002; Yang et al., 2003; Ramos et al., 2003) 
reacted poorly to the protocol. 
 In terms of DNA immunization, Balb/c mice seem to respond better compared 
to Balb/cJ with respect to their antibody responses to GST-Blo t 19 (Figure 33, Figure 
34).  Although both strains had low antibody titer against GST-Blo t 19, more Balb/c 
mice had a better antibody titer to GST-Blo t 19 than Balb/cJ. This was in contrast to 
the antibody responses obtained via i.p. delivery of protein with alum (Figure 32) 
where Balb/cJ responded better than Balb/c. 
Antibody responses of DNA immunized Balb/cJ 
























4.4.1 Unique Blo t allergen, Blo t 19 
A unique Blo t allergen, designated Blo t 19, was identified via screening of of 
λgt11 expression library of Blomia tropicalis. Blo t 19 shared 76% sequence identity 
with ASABF. The good alignment of Blo t 19 with both the nucleotide and amino acid 
sequences of the mature ASABF suggested that both proteins could potentially be 
evolutionarily linked. Blo t 19 is the first protein beyond nematodes that has high 
sequence similarity with ASABF.  
ASABF has been identified as a CSαβ-type antimicrobial peptide by 1H-NMR 
(Zhang & Kato, 2003). It was known that all CSαβ-type antimicrobial peptides had 
conserved cysteine array to give them their characteristic structure: a single α-helix and 
a pair of anti-parellel β-sheets (Bontems et al., 1991; Cornet et al., 1995; Dimarcq et 
al., 1998). ASABF could be considered distantly related to insect defensins (Dimarcq 
et al., 1998). Previous study showed that the cysteine array of ASABF was more 
identical to MGD-1 and myticin A, both antimicrobial peptides from two species of 
mussels: Mytilus galloprovincialis and Mytilus edulis, respectively than to other 
defensins based on cysteine array comparison (Zhang & Kato, 2003). It was 
demonstrated in this study that Blo t 19 had the same cysteine array as well (Figure 13), 
suggesting that Blo t 19 could have similar structure as these proteins. 
In terms of allergenicity, Blo t 19 did not seem to be a major allergen as far as 
the recombinant forms are concerned. Only around 10% of the subjects reacted to 
GST-Blo t 19 in ELISA. Nonetheless, it bound IgE in 16/20 sera from mite sensitized 
subjects in plaque immunoassay (Figure 14). One possible explanation was that GST-
Blo t 19 was not properly folded. The fact that Blo t 19 was relatively small compared 




discrepancy, native Blo t 19 is required. Therefore, effort was made to raise 
monoclonal antibody against this allergen with the hope that the native form of this 
allergen could be isolated. 
4.4.2 Monoclonal antibody generation 
The idea of using DNA immunization to induce antibody in mice for 
monoclonal antibody production experiments was based on similar experiments in the 
laboratory (Ramos et al., 2003; Wolfowicz et al., 2003; Yang et al., 2003). 
Monoclonal antibodies specific to Blo t 3 and Blo t 11 were successfully produced 
through DNA immunization (Ramos et al., 2003; Yang et al., 2003). 
4.4.2.1 Applications of AF6 (Blo t 19-specific mAb) 
A useful monoclonal antibody (AF6) specific for recombinant Blo t 19 was 
successfully raised. There was no question about the specificity of the antibody 
towards GST-Blo t 19 as shown by the specific inhibition of binding in ELISA (Figure 
27). Although absorption study with yBlo t 19 only reduced slightly in the binding of 
AF6 to GST-Blo t 19 (Figure 27), the fact that yBlo t 19 could be purified by using 
AF6 immunoaffinity column and also detected in ELISA showed that AF6 actually 
bound yBlo t 19. 
It was quite clear that AF6 could only give good signals in western blot when 
used to detect Blo t 19 in mite extract (Figure 29). This was not uncommon as other 
investigators also reported similar observations with other monoclonal antibody where 
it was shown that certain antibody was good for western blot but not for indirect 
fluorescence (Chestukhin & DeCaprio, 2003). It was possible that AF6 recognized 
linear epitope exposed only when Blo t 19 was denatured or misfolded. AF6 could 




misfolded form which favored the binding of AF6 whereas the native form of Blo t 19 
might have a different conformation. 
It was observed that both AF6 and I3D3 actually recognized GST-Blo t 19 
better than yBlo t 19 (Figure 26) albeit the mice were not exposed to GST-Blo t 19 at 
all during immunizations. On top of that, the hybridomas were screened using yBlo t 
19 and Blo t mite extract (Figure 25). This could be due to the small size of Blo t 19. 
The epitope of the yeast-expressed form probably could have been hidden or misfolded 
when coated onto the ELISA plates or transferred to membrane in western blot. In the 
case of GST-Blo t 19, because the size of GST was much larger than Blo t 19, the 
chances that it was absorbed to the plates and membranes was higher thus leaving Blo t 
19 free to interact with the antibody. This may explain the difference in the intensity of 
optical density reading in ELISA between GST-Blo t 19 and yBlo t 19 under the same 
concentration (Figure 27). 
4.4.2.2 Factors affecting the success of monoclonal antibody generation 
The shortcomings of this study were that it did not manage to raise more Blo t 
19 specific monoclonal antibodies and the screening process. More monoclonal 
antibodies would allow for more choices in choosing the right antibody for 
immunopurifications. The screening process involved recombinant proteins as antigens 
although the immunization processes mainly involved DNA delivery. Considering this 
issue, any antibody recognizing conformational epitope produced by the hybridomas 
could have escaped detection if the folding of the protein expressed in vivo in mice was 
different from those expressed in E. coli or Pichia pastoris. Moreover, initial DNA 
immunization did not raise significant amount of Blo t 19 specific antibodies in the 
mice (Figure 23). The antibody titer rose only after i.p. delivery of alum-coupled yBlo 




yBlo t 19 alone. Isotyping of the mice sera collected prior sacrifice showed that this 
was indeed the case (Figure 24). The mice sera indeed showed a high IgG1 titer 
compared to IgG2a, suggesting a Th2 response (Figure 24) (Raz et al., 1996). Gene 
immunization was known to induce primarily Th1 response which was signified by 
high titer of IgG2a. On the other hand, protein immunization induced Th2 response, 
with high IgG1 and often IgE production (Raz et al., 1996). In addition, it was known 
that protein immunization using recombinant proteins does not always produce 
antibodies that recognize native epitopes (Attanasio et al., 1997). Therefore, another 
fusion was performed using purely DNA immunization and I3D3 was obtained as a 
result. Nonetheless, the titer and affinity of I3D3 was too low to be of any use. 
Besides that, greater number of hybridomas generated did not favor the 
increasing chance of getting IgG-isotype antigen-specifc monoclonal antibody 
producing hybridomas. This observation was also obtained in similar study using 
another allergen, Blo t 12, where although hundreds of hybridomas were obtained, 
none was producing IgG-isotype antigen-specific monoclonal antibodies (unpublished 
data). 
It was observed that DNA immunization indeed induced lower titers of 
antibody compared to protein immunization as previously reported (Attanasio et al., 
1997). In fact, the antibody level induced by DNA immunization in this study was 
almost undetectable. Nevertheless, IgG-isotype monoclonal antibody (I3D3) could also 
be produced through DNA immunization. The only setback was that its titer and 
affinity was too low to be of any use. 
Different genetic background gave different degree of immune response to the 
same antigen (Berzofsky et al., 1977; Chatel et al., 2003). This was also demonstrated 




more responsive towards DNA immunization compared to Balb/cJ although Balb/cJ 
gave better response in protein immunization (Figure 33, Figure 34). Nonetheless, due 
to the small number of animals in each group (3-5 per group), no conclusive statement 
could be made. Further experiments were required to verify this observation. 
4.5 Conclusions and future directions 
 
In conclusion, a novel Blo t allergen, Blo t 19 has been identified. It is a 
probable antimicrobial peptide which has high amino acid sequence identity with 
ASABF, an antimicrobial peptide from Ascaris suum.  
 Recombinant Blo t 19 is a minor allergen. The allergenicity of native Blo t 19 
remains to be elucidated, as it has not been obtained successfully from the crude 
extract using monoclonal antibody column in this study. Further optimization of the 
experimental protocol is necessary in order to obtain the native Blo t 19. Nonetheless, 
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Acidic elution buffer (5 mM Glycine, pH 2.7) 
1 M Glycine (Sigma*)   
Milli-Q water  
Adjust to pH 2.7 





Agarose gel (1%) 
Seakem® LE agarose (BioWhittaker*)     
1 x TAE Buffer       
microwave mixture, add ethidium bromide (BioRad*) (final 
concentration=0.5 µg/mL). 










10% (w/v) Ammonium Persulfate (10% APS) 
Ammonium persulfate  (Amresco*)      
Top up to 10 ml with Milli-Q water. 




Ampicillin, 100 mg/ml 
Ampicillin, sodium salt (Calbiochem*) 
Top up with Milli-Q water to 50 ml, mix well, filter sterilize. Store 




Basic elution buffer (5mM Glycine, pH 11.0) 
1 M Glycine (Sigma*) 
Milli-Q water  
Adjust to pH 11.0 





500x Biotin (0.02%)  
Biotin (Sigma*)  








Biotinamidocaproate N-hydroxysuccinimide ester (Sigma*) 
Dimethylsulfoxide (DMSO) (Sigma*) 













Buffered Glycerol-complex (BMGY) Medium (per Liter) 
Yeast extract (Becton*) 
Peptone (Becton*) 
dissolve in 700 mL water and autoclave. Allow to cool and add: 
1 M potassium phosphate, pH 6.0 (Sigma*) 
10x Yeast Nitrogen Base (YNB) (Becton*) 
500x Biotin (Sigma*) 
10x glycerol (BDH*) 
 
10 g  
20 g  
100 ml  
100 ml  
2 ml  
100 ml 
Buffered Glycerol-complex (BMMY) Medium (per Liter)  
Yeast extract (Becton*)  
Peptone (Becton*)  
dissolve in 700 mL Milli-Q water and autoclave.  
Allow to cool and add:  
1 M potassium phosphate, pH 6.0 (Sigma*)  
10x YNB (Becton*)  
500x Biotin (Sigma*)  
10x Methanol (Merck*) 
To prepare Buffered Methanol-complex (BMGY) Medium, the 
Methanol was replaced with 10x glycerol (BDH*). 
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2 ml  
100 ml 
Coomassie stain 
Coomassie Brilliant Blue R-250 (BioRad*) 
Absolute ethanol (Sino*) 
Glacial acetic acid (Merck*) 








NaHCO3 (Sigma*)         
5 M NaCl 
Milli-Q water 
*Adjust to pH 8.3 















Destaining solution (for Coomassie staining) 
Absolute ethanol (Sino*) 
Glacial acetic acid (Merck*) 







Tris base (JT Baker*) 
NaCl (Merck*) 
Milli-Q water 










Developer solution (for silver staining) 
NaHCO3 (Sigma*) 
Top up to 1 litre with Milli-Q water. 






10x Dextrose (20%)   
D-glucose (Sigma*)  




1 M Dithiothreitol (DTT) 
Dithiothreiol (BioRad*) 
Sodium acetate (pH 5.2) 





0.5 M EDTA (pH 8.0) 
Disodium ethylenediaminetetraacetate (Na2EDTA.2H2O) (BioRad*) 
Milli-Q water 
Stir vigorously on a magnetic stirrer and adjust to pH 8.0 with 
around 20 g of NaOH pellets. EDTA will not dissolve completely 






Extration buffer 1 (For sensitization profile study) 
10X PBS 
0.5 M EDTA  
0.25 M PMSF 








Extration buffer 2 (For purification study) 
1X TBS 
0.5 M EDTA  
0.25 M PMSF 







Fixing solution (for silver staining) 
Methanol (Mallinckrodt*) 
Glacial acetic acid (Merck*) 






1 M Glycine 
Glycine (Sigma*) 




0.2 M Glycine (Elution buffer) 
1 M Glycine  
Milli-Q water  
Adjust pH to pH 2.85 










DMEM (Dulbecco’s Modified Eagle’s Medium 1X), HyClone* 
Fetal Bovine Serum, HyClone* 
HyQ Penicilin-Streptomyocin solution, HyClone* 
L-Glutamine, HyClone* 
HyQ Sodium Pyruvate, HyClone* 













Dissolve and adjust volume to 10 ml. Filter sterilized, store in -20ºC 






Luria Bertani Broth (Becton*)      
Top up to 1 litre with Milli-Q water. Sterilize by autoclaving and 




LB Agar with Ampicillin       
Luria Bertani broth (Becton*)       
Agar (Becton*)  
Top up to 1 litre with Milli-Q water and autoclave in liquid cycle. 
1 ml Ampicillin 100 mg/ml, added when agar cool to around 50°C. 





Maleic acid buffer 
Maleic acid (BDH*) 
NaCl (Merck*) 
Milli-Q water 
Adjust pH to 7.5 with NaOH pellet (Merck*) and top up to 1 litre 
with Milli-Q water. 
Washing buffer was prepared by adding Tween 20 to Maleic acid 






5 M NaCl 
NaCl (Merck*) 
Milli-Q water  






NZY Agar   
NaCl (Merck*)  
MgSO4 7H2O (Sigma*)  
Yeast extract (Becton*)  
Casein Hydrolysate (Becton*)  
Bacto Agar (Becton*)  
Top up to a final volume of 1 litre with Milli-Q water. Adjust pH to 
7.5 with NaOH (Merck), autoclave, and pour ~80 mL/145 mm plate. 
 
5 g  
2 g  
5 g  






10X Phosphate buffered saline  (10X PBS)  
NaCl (Merck*)   
KCl (Merck*)  
Na2HPO4.12H2O, (Merck*)  
KH2PO4  (Merck*) 
Adjust pH to pH 7.4 








10X PBS  
Tween polysorbate 20 (Duchefa*) 





0.25 M PMSF 
Phenylmethyl-sulfonyl fluoride (PMSF) (Sigma*) 
Absolute alcohol (Ethanol) (Hayman*) 





10% SDS  
Sodium dodecyl sulfate / Sodium lauryl sulfate 
Milli-Q water 
Heat to 68°C to assist dissolution, adjust to pH 7.2. Adjust volume 





2X SDS-PAGE Loading dye 
Milli-Q water     
1 M Tris-HCl pH 6.8  
Glycerol (BDH*) 
10% (w/v) SDS 
0.2% (w/v) Bromophenol Blue 
200 mM DTT 









Sensitizing solution (for silver staining) 
Na2S2O3 (Merck*) 




0.1% (w/v) Silver Nitrate Solution 
Silver nitrate (Merck*)  




Sodium deoxycholate 51.3 mg/ml 
Deoxycholic acid, sodium salt (Sigma*) 





Stop solution (for silver staining) 
Na2EDTA.2H2O (BioRad*) 








50X TAE Buffer (Tris-acetae/EDTA electrophoresis buffer) 
Tris base (JT Baker*) 
Glacial acetic acid (Merck*) 
0.5 M EDTA (pH 8.0) 







24% Trichloroacetic acid (TCA) 
100% Trichloroacetic acid (Merck*) 





1 M Tris 
Tris base (JT Baker*) 




1X Tris-Buffered Saline (TBS)  
1 M Tris  
5 M NaCl 
Milli-Q water 
Adjust to pH 7.5 






1 M Tris-HCl pH 6.8 
Tris base (JT Baker*) 
Milli-Q water 
Adjust to pH 6.8 





5X Tris Glycine Running Buffer 
Tris Base (JT Baker*)  
Glycine (Sigma*)  
Milli-Q water 
10% SDS (BioRad*) 
Adjust to pH to 8.3 







15% Tris Glycine Resolving Gel 
Milli-Q water  
40% Acrylamide/Bis Solution (BioRad*) 
1.5 mM Tris-HCl pH 8.8 
10% SDS  
10% APS  
N,N,N`,N`- tetramethylethylenediamine (TEMED) (BioRad*) 









4% Tris Glycine Stacking Gel 
Milli-Q water  
40% Acrylamide/Bis Solution (BioRad*) 












N,N,N`,N`- tetramethylethylenediamine (TEMED) (BioRad*) 
Mix well and dispense onto the solidified resolving gel 
 
0.010 ml 
0.5 mM Tris-HCl pH 6.8 
1 M Tris 
Milli-Q water 
Adjust to pH 6.8 





1.5 mM Tris-HCl pH 8.8 
1 M Tris  
Milli-Q water 
Adjust to pH 8.8 







5 M NaCl 
Milli-Q water  
Adjust to pH 8.3 






Western blot transfer buffer 
Tris base (JT Baker*)  
Glycine (Sigma*) 
Milli-Q water 
Adjust to pH 8.3-8.6 
Methanol anhydrous (Mallinckrodt*) 








X-Gal (40 mg / ml) 
X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) 
(Fermentas*) 
N, N-Dimethylformamide (Sigma*) 






10X YNB (13.4% Yeast Nitrogen Base with Ammonium Sulfate 
without amino acids) (per liter)  
Yeast Nitrogen Base (with ammonium sulfate, without amino acids) 
(Becton*)  






Yeast Extract Peptone Dextrose (YPD ) Medium (per Liter)  
Yeast extract (Becton*)  
Peptone (Becton*)  
Mili-Q water  





10 g  





Yeast Extract Peptone Dextrose (YPD ) Plates (per liter)  
Yeast extract (Becton*)  
Peptone (Becton*)  
Milli-Q water 
Agar (Becton*)  
Autoclave, add to 100 ml of sterile 10x dextrose (glucose), and pour 
to plates. 
 
10 g  
20 g  





Becton   
BDH   
BioRad  








JT Baker  
Mallinckrodt 
Merck   
Roche 




Amresco, Solon, Ohio, USA 
Becton Dickinson and Company, Franklin Lakes, NJ, USA 
BDH Laboratory Supplies, Poole, England 
BioRad, Hercules, CA, USA 
BioWhittaker Molecular Applications, Rockland, ME, USA 
Calbiochem®, EMD Biosciences Inc, San Diego, CA, USA 
Duchefa, Haarlem, Netherlands 
Fermentas, Vilnius, Lithuania 
GibcoTM, Invitrogen Corp, Carlbad, CA, USA  
Hayman, Essex, England 
HyClone, Logan, Utah, USA 
Janssen Pharmaceutica, Beerse, Belgium 
JT Baker, Phillipsburg, NJ, USA 
Mallinckrodt Inc, Hazelwood, MO, USA 
Merck, Darmstadt, Germany 
Roche Pharma (Schweiz) AG, Basel Switzerland 
Sigma Chemical Company, St. Louis, MO, USA 
Sino Chemical Co (PTE) Ltd, Singapore 
Whitehall Lab Pty Ltd., Punchbowl, Australia 
 
     pH are adjusted using either HCl (Merck*) or NaOH (Merck*) unless otherwise  
     specified. 




Appendix B: Vectors 
pGEX-4T-1 expression vector (Amersham Biosciences, Buckinghamshire, 
England) 
 







pCI mammalian expression vector (Promega, Madison, USA) 
Vector size: 4 kb 
 Position 
Cytomegalovirus immediate-early enhancer/promoter region 1-795 
Chimeric intron 857-989 
T7 RNA Polymerase Promoter (-17 to +2) 1034-1052 
T7 promoter transcription start site 1051 
Multiple cloning region 1052-1104 
SV40 late polyadenylation signal 1111-1332 
Phage f1 region 1422-1877 
Beta-lactamase (AmpR) coding region 2314-3174 
 
 
pCI mammalian expression vector map  
(Source: www.Promega.com) 
 
Der p 5 leader sequence 
                    BspE1 
5’ TCGAGATCAATCATGAAATTCATCATTGCTTTCTTTGTTGCCACTTTGGCAGTTATGACTGTTTCCGGA 3’  
3’ AGCTCTAGTTAGTACTTTAAGTAGTAACGAAAGAAACAACGGTGAAACCGTCAATACTGACAAAGGCCT 5’ 
 
Sequences in bold is the Der p 5 sequence. Underlined sequence is the restriction 




pCR®2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) 
Vector size: 3.9kb 
 Position 
LacZα fragment   1-571 
M13 reverse priming site 205-221 
Multiple cloning site 234-357 
T7 promoter / priming site 364-383 
M13 Forward (-20) priming site 391-406 
M13 Forward (-40) priming site 411-426 
F1 origin 548-962 
Kanamycin resistance gene 1296-2090 
Ampicillin  resistance gene 2108-2968 
ColE1 origin 3113-3786 
 
 
pCR®2.1-TOPO vector  
(Source: www.Invitrogen.com) 
 
